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11. Summary
The etiology of Alzheimer’s disease (AD) remains a great challenge for neurological research.
Extensive investigations for almost one hundred years have led to profound insights of the
pathological and molecular mechanisms that affect the AD brain, and there are several
hypotheses about what causes the characteristic AD related dementia. The focus has fallen
increasingly on the deposition of ß-amyloid (Aß) in the cortex and it is believed, that the
generation and deposition of Aß is the leading cause of the disruptions observed in the AD
brain. Aß has been shown to provoke neuron death, decreased synaptic plasticity, aberrant
sprouting of growing axons, chronic inflammation and hyper-phosphorylation of tau.
In recent years, research on adult neurogenesis in the mammalian brain has led to surprising
findings: new neurons are added daily to specific regions of the brain and growing evidence
suggests that these new neurons play a critical role for learning and memory, mood and, to a
limited amount, repair of damaged cortical areas. All of these functionalities of neurogenesis
are affected in AD patients and the question must be raised, if in the AD brain, neurogenesis
is directly disturbed. Defects in neural stem cell biology might significantly contribute to AD
dementia and the examination of the relationship of AD lesions and neural stem cell biology
might provide new insights for the understanding and treatment of AD.
Only recently has it become possible to investigate neural stem cell biology in the AD brain.
This is partly because only recent findings revealed the function of adult neural stem cells, but
also because animal models for AD have only been available for few years. However, most
AD mouse models, which are genetically engineered for Aß deposition, do not develop
significant amyloid plaques until past their median lifespan. This limits their availability and
the specificity to Aß is reduced due to accompanying age effects.
In a first study of this thesis, age related changes of neurogenesis were investigated by
monitoring the progressive stages of hippocampal neurogenesis: proliferation, survival and
differentiation, in four different age groups of wild type C57BL/6J mice. Net-neurogenesis
was rapidly reduced in adult compared to young mice, but remained stable at a low level in
aged and senescent mice. This effect could be attributed mostly to an age related decline of
proliferation with a concomitant increase of survival rates in aged mice. These results suggest
that neurogenesis in aged mice remains as functional as in adult mice, although the plasticity
of the neurogenic system appears to be reduced compared to young mice. The finding that a
2reduced caloric diet, a treatment known to reduce age related defects, did not have an effect
on neurogenesis confirmed the finding that neurogenesis is not impaired in aged mice
compared to adult mice.
In a second study neurogenesis was studied in APP23 mice, a transgenic AD mouse model
with progressive amyloid plaque load. Adult Aß pre-depositing and aged Aß high-depositing
mice were investigated. Surprisingly, aged APP23 mice showed an increased number of new
neurons in the hippocampus compared to age matching controls. For a closer investigation of
the interaction of neural stem cells and Aß, we crossed mice expressing GFP under a stem cell
specific promoter with a new AD mouse model with cortical plaque deposition in early
adulthood. Stem cells were reduced in numbers, strongly attracted to Aß and morphologically
altered. In addition, the population of more differentiated immature neurons appeared to be
morphologically unaffected by Aß. These findings show that Aß affects neural stem cell
biology concomitant with an up-regulation of neurogenesis.
Several reports claim that stem cells from the periphery are able to cross the blood brain
barrier and are able trans-differentiate to the neuronal lineage. It has also been shown, that the
number of cells immigrating from the periphery increases in AD mouse models. Thus, in a
third study we investigated if stem cells from the peripheral hematopoietic system could
participate in the repair or replacement of the damaged neuronal tissue. APP23 mice were
deprived of their immune system by gamma irradiation and later reconstituted with
genetically marked hematopoietic stem cells. We found a large number of these cells invading
the brains of aged APP23 mice, but cell fate analysis revealed that these cells matured to
macrophages or T-cells, but none differentiated towards the neuronal lineage. We conclude
that the hematopoietic system is involved in the immune response in the brain, but we found
no evidence that it is involved the in repair of the damaged network or in the alterations of
neural stem cell biology described above.
In conclusion, the results of the present thesis provide evidence of a defective behavior of
neural stem cells in the amyloidogenic brain, but also unveil the limitations in the function
and ability of neural stem cells in the aged brain.
32. Introduction
2.1. Stem Cell Biology
Stem cell research has opened one of the most fascinating chapters in the history of biology.
Traditionally belonging to the field of developmental biology, stem cells have become of
increasing interest for biomedical research in more recent years. Tissue engineering,
therapeutic cloning, transgenic animals and gene therapy are among the most discussed
applications.
2.1.1. Background
Stem cells are undifferentiated cells that can divide indefinitely. They can either divide
symmetrically, producing two identical daughter cells, or asymmetrically producing one
identical and one more differentiated daughter cell 1. The least differentiated stem cell type is
the omnipotent or totipotent stem cell. It is found in early mammalian embryos (4 – 8 cell
stage) and can form any cell type or tissue including the entire fetus and the placenta 2. The
inner cell mass of the blastocyst contains pluripotent stem cells 3. These embryonic stem (ES)
cells can be maintained in an undifferentiated state in culture, can differentiate in virtually any
kind of cell type, but are not capable of forming an entire embryo. ES cells can be
differentiated into multipotent stem cells, which are restricted to their specific lineage. These
are hematopoietic, mesenchymal, endodermal or neural stem cells. These lineages follow
specific differentiation patterns, with increasingly specialized cells. For example, neuronal
stem cells can differentiate into glial-restricted progenitors, motor neuron progenitors, neural
crest stem cells and neuron restricted progenitors. By applying the appropriate clues in a
defined order it is possible to direct an ES cell towards a specific cell type 4. However, the
controversy over using human embryos as a source of these cells have led to intensified
research to find ES-like cells in the adult, and to reverse the differentiation process to the
pluripotent level 5,6. Although some groups claim to have gained stem cells from skin, bone
marrow or hair-follicle, these cells are often restricted to a distinct lineage (for these
examples: mesenchymal, hematopoietic or neuronal, respectively). Thus, the only source of
ES-like cells from the adult remains somatic cell nuclear transfer (referred to as therapeutic
cloning).
42.1.2. Adult stem cells
For five decades hematopoietic stem cells have been the only adult stem cells known and
investigated. Recently it was discovered, that numerous adult tissues contain stem cells.
Normally these cells are involved in the homeostatic self-renewal and regenerative processes,
but are occasionally activated for repair activity (for review see 7). The lumen of the intestine
for example is replaced about once a week. Blood and skin is renewed constantly, hair and
nails constantly grow. All these systems depend on small local populations of stem cells,
which are highly regulated. If the specific program of proliferation, migration and
differentiation fails, the respective tissue will either become dysfunctional or cancerous. The
arrangement of these proliferative systems is surprisingly conservative for the different tissues
where adult stem cells are found. Generally a population of stem cells is harbored in a defined
niche. The stem cells proliferate slowly, maintain the size of population and produce another
population of transient amplifying precursor cells. These proliferate at a higher rate, and
migrate towards the final destination of the specific mature cell type. This results in a
differentiation gradient from the stem cell along to the migratory precursor cell to the fully
differentiated cell (Fig. 1).
Fig. 1: Schematic representation of adult stem cell differentiation. The differentiation process starts by
asymmetric division of stem cells in a specific niche and continues during the migration towards the target tissue
(green). The intensity of red background signifies the degree of differentiation.
52.2. Adult Mammalian Neurogenesis
2.2.1. Neurogenesis in the adult brain
It has been a common understanding that in postnatal mammals no new neurons are added to
the CNS and that any further changes can only be adopted through rewiring of the synaptic
connections. In fact this dogma originates from early works at the end of the nineteenth
century describing the developmental and adult brain of humans and other mammals 8-10.
These investigators found that the architecture of the brain appears to be fixed soon after
birth. At the cellular level, neither mitotic nor developing neurons were observed. Although
there were occasional reports on mitotic cells in the brain of adult mammals 11,12 there were no
convincing methods to prove that these new cells would differentiate into neurons and be
functionally integrated. Using autoradiography to track H3 Thymidine, incorporated by
proliferating cells during mitosis, Joseph Altman published a series of papers in the nineteen
sixties showing evidence for adult neurogenesis in the adult rat and cat (for review see 13). The
scientific community did not recognize the significance of his results. Although Altman’s
experiments were repeated and combined with electron microscopy, and additional evidence
for neurogenesis in songbirds was presented 14,15, the observation of neurogenesis in the adult
brain did not get much attention. In the nineteen nineties new techniques emerged. Instead of
tritiated Thymidine, Bromodeoxyuridine (BrdU) was used as a proliferation marker. BrdU
can easily be labeled with immunohistochemical methods and investigated with brightfield
and fluorescence microscopy. In addition specific antibodies against neuronal or glial markers
were developed, providing easy methods to distinguish neurons from glia. With the help of
these methods adult neurogenesis has been demonstrated to exist until senescence in
numerous mammalian species including humans 16. Finally, the neuronal behavior and
integration into the network was confirmed by experiments testing long term potentiation
(LTP), synapse formation and expression of immediate early genes after stimulation of the
hippocampal network 17-20.
62.2.2. Neurogenic regions
In mammals three areas of ongoing neurogenesis have been identified: The subventricular
zone (SVZ), the olfactory bulb (OB) and the granular cell layer (GCL) in the hippocampus
(Fig. 2). Neural stem cells from other brain areas like the neocortex or the thalamus have been
isolated in vitro by dissecting these areas and growing the precursors in a growth factor rich
medium 21, but in vivo these cells appear to remain quiescent and have not been observed in
an activated state. Three subtypes of cells have been identified in the SVZ 22. ‘Astrocyte-like’
or ‘Type B’ stem cells cells are positive for glial fibrillary acid protein (GFAP) and most
evidence suggests that this is the least differentiated neural stem cell. It has also been shown
in embryonic tissue that radial glia cells can differentiate into neural precursor cells and one
group was successful in re-differentiating neural precursor cells into radial glia 23. Neural stem
cells divide slowly in an asymmetric way, producing astrocyte-like cells and rapidly dividing
precursor cells (type C). Type B cells and clusters of type C cells form channels within which
the neuroblasts migrate along the sub ventricular zone. The migrating neuroblasts were named
type A cells and differentiate from type C daughter cells. The SVZ provides the OB
constantly with a stream of progenitor cells, through a path called the rostral migratory stream
(Fig. 2).
Fig. 2: Sagittal section of a mouse brain showing the neurogenic regions by immunhistochemical staining of
immature neurons (DCX).
7The migratory neuroblasts divide until they integrate as granular cells in the OB. Only very
few mature new neurons originating from the SVZ invade the rest of the cortex. This was
only found after distinct lesions and not in significant enough numbers to replace the cells lost
in the incident 24,25. In the dentate gyrus of the hippocampus there is a similar progression of
differentiation, but within a different architecture (Fig. 3). Stem cells located in the
subgranular layer produce cluster forming precursors. From there, neuroblasts migrate into
the GCL were they extend dendrites into the molecular layer (ML) and send mossy fibers to
the CA3 region (Fig. 4). Many more cells are generated than the number that ultimately
survives. Following the principle ‘use it or lose it’ the survival depends on how sufficiently
the new cells are activated by incoming neural signals. From the neural stem cell to the
mature neuron the cells go through defined steps of division, differentiation, migration and
maturation. Using specific markers it is possible to investigate the different phases of
development separately (Fig. 3).
Fig. 3: Differentiation of neural stem cells into granule cells in the GCL. It is still debated if precursor cells can
dedifferentiate to stem cells. The different stages can be monitored by differential expression of specific proteins.
Nestin and DCX is co-expressed for a very short time, and DCX and NeuN is not co-expressed.
82.2.3. The neurogenic niche
Like all adult stem cells, neural stem cells are restricted to a particular niche. Interestingly, in
the brain this is closely associated with the angiogenic niche 26. Therefore, neural stem cells
are always located close to the vasculature, and even react to the same stimuli as the
endothelial stem cells do. This is even more astonishing, as neurogenic and endothelial stem
cells are thought to arise from different lineages. However, a recent study reports that neural
stem cells have been observed to differentiate into endothelial cells 27. In vitro studies have
shown that both endothelial cells and astrocytes can provide various factors to regulate
neurogenesis in the vascular niche 28,29, and suppression of neurogenesis by irradiation was
accompanied by a destruction of the niche 30.
2.2.4. Regulation of neurogenesis
Since the general recognition and acceptance of adult neurogenesis a large amount of studies
have been conducted to investigate how neurogenesis is regulated. We know that Amphibians
and Fish can regenerate neuronal tissue in the retina (for review see 31) and findings from the
investigations of retinal repair mechanisms have induced a multitude of experiments to study
mammalian neurogenesis. The goal is to stimulate the neurogenic capabilities in the brain to
induce an endogenous repair mechanism of the damaged mammalian CNS. These studies
have revealed a complex regulative interaction of hormones, growth factors, cytokines and
neurotransmitters conducted by environmental inputs like physical exercise, enriched
environment or learning experiences.
Adrenal steroids may be one of the most important neurochemical regulators of neurogenesis.
An increased plasma levels of corticosterone, as it appears as a reaction to applied stress, has
negative effects on hippocampal neurogenesis 32-34. Depleting the system from corticosterone
by adrenalectomy reverses this effect. The influence of estrogen is more complex;
ovariectomy decreases GCL precursor proliferation and if plasma levels are reconstituted,
hippocampal neurogenesis is increased in the first hours. But if plasma levels stay high over
prolonged time, an overall suppression of proliferation is observed 35,36. Estrogen induced
positive stimulation of proliferation is mediated by serotonin, downregulation of proliferation
is mediated by adrenal steroids 36,37. Estrogen as a positive regulator of neurogenesis is further
modulated by interaction with IGF-1 38.
9IGF-1 itself is an important growth factor neurogenesis highly depends on. Plasma levels of
IGF-1 are increased by exercise and this promotes major increases in GCL precursor
proliferation 39. This systemic IGF-1 is mostly synthesized in the liver and enters the brain
through endothelial cells. It can be blocked by subcutaneous injection of an antibody against
IGF-1, which blocks exercise induced increases of proliferation 40, or it can be simulated by
peripheral injection of IGF-1 41. Like IGF-1, neurogenesis is stimulated by peripheral FGF-2
and VEGF, and similar experiments with subcutaneous injections of growth factors and
antibodies were successfully performed 42,43. However, even if growth factors from the
periphery are blocked, a low level ‘baseline neurogenesis’ is observed in the GCL. This is due
to local expression of these growth factors by astrocytes and neurons 43,44. In addition, the
regulation of baseline neurogenesis depends on other locally produced growth factors like
EGF or BDNF and is further modulated by co-factors, such as Cystatin C and heparin, which
facilitate growth factor binding to their receptors 45,46. BDNF is a growth factor expressed in
the hippocampus without further supply from the periphery. The up-regulation of BDNF
expression is mediated through serotonin and noradrenalin, which also explains the high
levels of BDNF and neurogenesis after antidepressant treatment 47,48.
Down regulation of neurogenesis has been reported from cytokines expressed as part of an
inflammatory response. Induction of inflammation by LPS injection leads to an abrupt down
regulation of neurogenesis. But this negative response to inflammation can be prevented with
NSAIDs or with a blocking antibody against the cytokine IL-6 49. The suppressive effect of
IL-6 on neurogenesis was also confirmed in a transgenic mouse engineered to over express
IL-6 in the brain 50. Another cytokine, CNTF promotes self renewal of stem cells and prevents
the progeny from differentiating 51. CNTF transmits its signal through gp130 and LIFR and
promotes the expression of NOTCH, an inhibitor of neuronal differentiation 52,53.
The positive neurogenic influence of serotonin was already mentioned, but also the
neurotransmitters dopamine and acetylcholine were found to directly stimulate neurogenesis
54,55. It is therefore not surprising, that psychoactive drugs such as lithium and selective
serotonin reuptake inhibitors as well as haloperidol (a dopamine antagonist) increase
neurogenesis 56-58. Deleterious drugs to neurogenesis are morphine, metamphetamine and
alcohol 59-61.
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The cortex is wired to the hippocampus through the entorhinal cortex (Fig. 4). This input
connection has direct influence on neurogenesis; it has been shown that excitatory input from
the entorhinal cortex through the NMDA receptor suppresses neurogenesis, while inhibition
of this pathway through the blockage of NMDA receptors or the removal of input enhance it
62.
Finally, there are indications that neurogenesis can react to CNS insults. Brain injury through
cerebral ischemia, seizure or neurotoxic lesion all lead to an increase of neurogenesis 63-65.
However, in all these experiments the damage was far greater than the response and the
ability of neurogenesis to repair the damaged tissue seems very limited
Fig. 4: Organization of the hippocampal formation within the mouse brain. A: Schematic representation of the
location of the hippocampus within the mouse brain. Enlarged is a coronal section through the hippocampus
highlighting the basic circuitry B: Circuit diagram of the basic information flow in the hippocampus. EC:
entorhinal cortex: DG: dentate gurus; S: subiculum; green: granular cell layer; yellow: CA3 and CA1.
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2.2.5. Neurogenesis and memory
The hippocampus is a brain structure critical for the formation and processing of memories. In
humans it is involved in declarative memory, so called because of the involved synthesis of
episodic representations and semantic knowledge. The hippocampus is especially important
for the formation of memories in new situations that require an inference on the basis of
linking distinct experiences in memory. Patients with a damaged hippocampus suffer from
global anterograde amnesia, but normal cognitive function, immediate memory, remote
childhood memories, and general world knowledge acquired early in life are not impaired 66-68.
In laboratory animals this is tested in hippocampus dependent spatial or temporal learning
tasks 69,70. The circuitry of the neuronal processing has been extensively studied and consists
of a unidirectional message flow through the hippocampal subfields as well as direct inputs to
all those subfields (Fig. 4). Studies on specific firing patterns of single neurons within this
circuitry have revealed, that single neurons in the hippocampus are directly linked to spatial,
and temporal memories, e.g. when a mouse walks through a maze, the same cell will fire
whenever the mouse passes through a specific location. These cells where named place cells
and the corresponding location the place field 71.
Recently published experiments suggest, that field representations within the entorhinal
cortex are context-independent, while in the hippocampus they are context-dependent 72,73.
This means that the spatial organization of an environment is represented in the entorhinal
cortex, but this is further processed in the hippocampal subfields in a temporal, social,
emotional, etc context. These results seem to confirm previous findings that simple memories
may be formed with a damaged hippocampus but inferential computing is impaired. In a
classic transitive inference task animals learn a series of overlapping pair wise discrimination
problems (A > B, B > C, C > D, D > E). Control animals can learn that B > D, animals with
hippocampal damage are not able to do this transition 74. Similarly, in a Morris water maze
test animals with a damaged hippocampus are only slightly impaired to learn the location of
the submerged escape platform when the starting point within the maze remains constant, but
are unable to learn when the starting point is different from the previously learned one 75.
It is striking that neurogenesis occurs in the GCL of the dentate gyrus, a structure so central in
the hippocampal memory system. However, only recently first links of memory and
hippocampal neurogenesis could be established. Voluntary running and an enriched
environment have both been shown to increase neurogenesis, this has been shown to be
accompanied by improve performance in memory tasks 17,76,77. When an anti-mitotic agent was
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applied during environmental enrichment, memory did not improve, as neurogenesis did not
increase 77. Similarly, when VEGF, a growth factor through which an enriched environment
increases neurogenesis is blocked, the beneficial effects of an enriched environment on
neurogenesis and memory are lost 76. Also blockage of neurogenesis can lead to substantial
memory impairments, this has been shown by using a toxin for proliferating cells 78 and
irradiation 79,80. Learning abilities can be trained and therefore it is not surprising, that learning
increases neurogenesis 81. Plasticity seems to be especially high in newborn neurons in the
GCL 82,83 and LTP in the dentate gyrus is increased after running 17. Other studies on how
neurogenesis is working in the system of memory formation suggests that, new neurons are
important for memory clearance, and an impaired neurogenesis inhibits this clearance 84,85.
Computational models of the hippocampal learning structure predict, that increasing the
number of replaceable neurons in the dentate gyrus would increase the capacity for learning
new information and forgetting old information 86. Although the involvement of adult
neurogenesis in hippocampal learning and memory has only been studied for a brief period of
time, the multitude of evidence suggests that it is indeed involved in this process, rather than
being a residual of an evolutionary outdated repair ability.
2.2.6. Neurogenesis in the aging hippocampus
In the aging brain, neurogenesis remains functional, but the number of newly generated
neurons declines gradually 87,88. Is this the reason for age related impairments in learning
capacity and if so what is the reason for this and why can’t it been prevented? It was found
that adult stem cells, in a variety of tissues, proliferate more slowly and become less
productive in the aged. This may be because adult stem cells do have limits in their
replication capabilities. As a result of the biochemistry of DNA replication 20-50 base pairs at
the end of the chromosomes remain un-copied. To prevent damage to the genetic information,
chromosomes have an extended DNA tail called the telomere. In ES cells the telomere is kept
at a constant size by telomerase activity, but in adult stem cells telomerase activity is limited
and they eventually reach senescence by telomere shortening 89. A slower rate of proliferation
might simply prevent these cells from becoming dysfunctional or cancerous. This hypothesis
is underscored by a recent study finding that adult stem cells with reduced telomere length
and decreased telomerase activity display a suppressed level of mitotic and migratory activity
90.
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This lower level of neurogenesis starts in middle aged animals and is controlled by a reduced
expression of the growth factors neurogenesis depends on. Indeed the down regulation of
growth factors follows the same pattern as the down regulation of neurogenesis 87,91. When
factors like IGF, FGF or EGF are administered, neurogenesis can be elevated, but only to
about 20% of the level seen in juveniles 46,92. In fact, it has been postulated, that growth factor
levels can not only influence neurogenesis and cognition, but also have direct influence on an
animals lifespan 93.
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2.3. Alzheimer’s Disease
One hundred years ago, 1906, the German psychiatrist Alois Alzheimer (1864-1915)
presented the case of a 54 years old woman who suffered from progressive dementia. He
described the clinical and pathological symptoms for the first time, now known as
Alzheimer’s disease 94.
2.3.1. Clinical symptoms
AD is a progressive dementia with memory loss as the major clinical manifestation.
Impairment of short-term memory is often prominent, but remote memory loss also appears to
be affected over time. Other important features of AD are an altered behavior including
paranoia, delusions, depression, impairments of attention, perception, reasoning and
comportment, and a progressive decline in language function 95,96. Normal aging does not
necessarily imply that memory function remains intact 97. However, the onset of AD related
dementia is preceded by a transitional preclinical period of many years during which
relatively isolated memory difficulties exceed those expected on the basis of normal aging
without becoming severe enough to interfere with daily living activities 98,99. The capacity for
independent living wanes when mental functions and activities of daily living become
progressively impaired 100. However, motor functions remain initially intact but deteriorate in
the final phase of the disease, leading to symptoms resembling motor disorders such as
parkinsonism 101.
2.3.2. Pathophysiology
The main neuropathologic findings in the AD brain are amyloid plaques, neurofibrillary
tangles and a degeneration and loss of synapses and neurons. Amyloid plaques are
multicellular lesions containing extracellular deposits of amyloid-β protein (Aβ) consisting of
amyloid fibrils (7-10 nm) intermixed with non-fibrillar forms of the Aβ peptide. The plaques
are surrounded by dystrophic neurites, consisting of both axonal terminals and dendrites.
Plaques often contain activated microglial cells situated near the amyloid core, reactive
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astrocytes are found more at the periphery of the plaque 102,103. Another form of Aß-deposition
appears as diffuse or pre-amyloid plaques, where Aβ occurs in a non-fibrillar, less dense and
amorphous form in the neuropil 104,105. In brain regions with less significance to AD, like the
cerebellum, the striatum and the thalamus, most Aβ deposits are diffuse with little or no glial
and neuritic reactions 104,106. Extracellular Aβ deposits are also found in the walls of cerebral
and leptomeningeal blood vessels. This cerebral amyloid angiopathy (CAA) can be found in
absence of AD. However, at the age of sixty and over CAA is detected in 30 % of the general
population, compared to 80% in AD patients 107,108. A growing amount of scientists support a
theory called ‘the amyloid cascade hypothesis’, which states that the accumulation and
deposition of Aβ in the brain is the primary influence driving AD pathogenesis and leading to
neuronal dysfunction 109.
Neurofibrillary tangles are intra neuronal paired helical filaments composed of
hyperphosphorylated isoforms of the microtubule-associated protein tau protein, which in
normal cells is essential for axonal growth and development 110. Neurofibrillary tangles
generally occur in large numbers in the AD brain, particularly in neurons located in the
entorhinal cortex, hippocampus, amygdala and frontal association cortex leading to cell death.
The tau protein normally enhances the polymerization of tubulin into microtubules and
stabilizes these organelles in neurons. But when it becomes excessively phosphorylated its
affinity to microtubules is reduced 111. Neurofibrillary tangles form in some cell bodies whose
axons terminate in regions containing Aß 112. It has been shown in mouse models that in these
cases Aß leads to tangle formation, confirming the amyloid cascade hypothesis 113,114. The AD
brain is characterized by extensive neuronal and synapse degeneration found throughout a
similar pattern as the neurofibrillary tangles 115-118. In addition neuronal loss in the nuclei of
major neurotransmitter pathways is prominent. The death of cholinergic neurons in the
nucleus basalis of Meynert, serotonergic neurons in the median Raphe nuclei or adrenergic
neurons in the locus coeruleus leads to a deficit in acetylcholine, serotonin or norepinephrine,
respectively 119-121.
2.3.3. Epidemiology and genetics of Alzheimer’s disease
Over 50% of the typical, late-onset cases of dementia are diagnosed as AD, and it is therefore
the most common form of dementia in the elderly. The number of patients worldwide is
estimated at approximately 20 million and is expected to keep growing as the current
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population ages. At the age of 65 the risk of developing AD is estimated to be not more than
2%, but raises to 10-15% at the age of 80 122-124. Cognitive impairments start during the
seventh decade in most individuals with AD, but may appear earlier, particularly in familial
cases 125. However, most AD cases are sporadic and occur with no clearly defined etiology.
Familial AD (FAD) is autosomal dominant inherited, and except for the early age of onset
(<60 years), clinically and pathologically indistinguishable from sporadic AD 126,127. The
proportion of Alzheimer cases that are genetically based is estimated between 5% and 15%
128,129.
The observation of an increased incidence of AD among older Down syndrome patients lead
to a closer investigation of chromosome 21, and finally to the first genetic linkage discovery
between a locus on chromosome 21q and FAD 130,131. Screening of the sequenced APP gene
for mutations led to the discovery of several missense mutations 132-134. Most FAD cases do
not have a mutation on APP, but a second locus on chromosome 14 was identified, and the
gene was later isolated and named presenilin 1 (PS1) 135,136. PS2 was found based on its
homology to PS1 and mapped on chromosome 1 137. Other genetic risk factors have been
identified that increase the risk of developing sporadic AD. These include the ε4 allele of the
apolipoprotein E (APOE) gene, the proteinase inhibitor α2-macroglobulin, low density
lipoprotein receptor-related protein (LRP), angiotensin converting enzyme (ACE) or insulin
degrading enzyme (IDE) 138-142. All of these risk factors of sporadic AD and the autosomal
dominant mutations of FAD are involved in secretion, clearance or degradation of Aß protein,
the primary component of β-amyloid plaques in the brain 143,144.
2.3.4. APP processing and Aβ
APP is a type-I integral transmembrane glycoprotein that is ubiquitously expressed, but the
physiological function of APP in the brain remains unclear. It has been proposed to have
functions in transmembrane signal transduction, calcium regulation, cell proliferation, cell-
adhesion, neurite outgrowth and synaptogenesis 145-150. This is reflected in APP knock out
mice, which show cognitive deficits and reduced synaptic plasticity 151,152. APP is processed
by α-, β- and γ-secretase (Fig. 5). In the default, non amyloidogenic cleavage pathway, α-
secretase cleaves within the Aβ region to produce the soluble α-APP  (sAPP) and the 83
amino acid COOH-terminal fragment C83 153,154. Alternatively, processing with ß-secretase
produces a 99 amino acid C-terminal (C99), which includes Aß 155 and a longer form of sAPP.
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Both the C83 and C99 fragments remain anchored in the membrane where they are processed
by γ-secretase to produce p3 from C83 or Aβ from C99 (Fig. 5). γ-Secretase cleavage occurs
within the membrane, but is not sequence specific resulting in Aß peptides of varying length.
The most common form is Aß40, but there is always a percentage of Aß42, which is less
soluble and more likely to form toxic aggregates 156. Extensive research has revealed that γ-
secretase is a multi-protein high molecular weight complex and consists of presenilin-1 (PS1),
presenilin-2 (PS2), nicastrin (Nct), anterior pharynx-defective phenotype (APH-2) and PS-
enhancer (PEN-2) all of which are essential for its function 157-160.
Fig. 5: Proteolytic processing of APP by α-, β- and γ-secretase and the resulting protein fragments. Aß can only
be produced through the ß-secretase pathway, while processing with α- secretase prevents Aß formation.
Mutations on APP that cause familial AD are localized within the Aβ domain near the cleavage sites of the
secretases, here marked in green, grey and yellow.
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Missense mutations on the APP gene that have been linked to FAD are all located at the
cleavage sites of α-, β- and γ-secretase. The different mutations have been named after the
geographic area the FAD inheriting family lived in, e.g. Swedish, Dutch or London 132,134,161.
FAD mutations at the α- or β- secretase cleavage site favor ß-secretase cleavage, and
therefore increase Aß production over p3 production 162. Mutations at the γ-site promote the
production of Aβ42 over Aß40 163. Both increased Aß production and a higher rate of Aß42
are responsible for increased deposition of Aß plaques.
2.3.5. Mouse models of Alzheimer’s disease
The identification and sequencing of APP and presenilin opened the door for the engineering
of transgenic mouse models to study pathogenic mechanisms of AD. The first successful
mouse models over-expressed human APP with an FAD linked mutation in the brain. These
mice exhibit Aß plaques, neuron loss, dystrophic neurites, inflammatory responses, learning
impairments and deficits in synaptic transmission and/or long-term potentiation 164-169 (Fig. 6).
The severity and onset time of AD like pathology is influenced by the level of transgene
expression and the specific mutation. Other models combine the insertion of mutated APP
with an insertion of mutated PS1, or insert APP with two mutation sites to have an even
stronger phenotype 170,171. None of these Aß depositing mouse models develop tau filaments.
This has only been shown in mice expressing mutant human tau protein or by combining Aß
deposition with a mutation in the tau gene 113,114,172.
Fig. 6: Amyloid plaques and glial reaction in transgenic APP23 mice. A: Immuno staining of Aß reveals large
deposits in the hippocampus of a 24 month-old APP23 mouse. B: Projection of a stack of multiple confocal
images demonstrating the distribution and morphology of microglia (red) around Aß plaques (green). Cell
nuclei are stained blue. C: Three dimensional reconstruction of astrogliosis in APP23 mice; green: Aß; red:
astroglia; blue: cell nuclei.
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2.4. Synthesis: Neurogenesis in the AD Brain
Given the complexity of the regulatory system of neurogenesis and the profound changes that
are found in the AD brain, an altered behavior of neural stem and progenitor cells can be
assumed. It is tempting to hypothesize that memory loss of AD patients is related to a
disturbed neurogenesis in the hippocampus, and therefore a potential target for therapy. Even
if neurogenesis is not directly impaired in AD, compensation for neuron loss in the
hippocampus by controlled stimulation of endogenous neurogenesis might restore some of the
lost hippocampal function. However, few studies about the influence of AD on neurogenesis
have been published. Only one study investigated neurogenesis in AD patients 173. The
expression of markers of neurogenesis like DCX (a microtubuli binding protein in
neuroblasts), PSA-NCAM (a plasma membrane glycoprotein expressed by neural progenitors)
or NeuroD (a basic Helix-loop-helix protein expressed during neuronal differentiation) was
measured in western blots from post mortem hippocampal tissue. Significant increases of
these ‚neurogenic’ proteins in AD brain led to the conclusion that neurogenesis is increased.
However, other brain insults like ischemia or seizure, or brain damage through neurotoxic
compounds tend to provoke an increase of neurogenesis or at least an increased proliferation
rate of neural stem cells 63-65.
2.4.1. Influence of APP and Aß on neurogenesis
Neurogenesis has been investigated in AD mouse models, but the mouse models and methods
differ and the results are controversial. In two different mouse lines expressing human APP
with the Swedish mutation up to the age of 12 months, lower levels of precursor proliferation
and survival compared to wild type littermates are reported, but only in one of these studies
impairment in proliferation was reported at 3 months of age, therefore before Aß plaques are
found 174,175. In another mouse line expressing human APP with the Swedish and the Indiana
mutation, proliferation is lower at 3 and 12 months 176. Most of these mouse models over
express APP, but often it is not known to what degree. It has been shown that sAPP can act as
a growth factor by binding to neural precursor cells and blockage of sAPP can decrease
neurogenesis in vivo 150. In addition, APP seems to have an anti apoptotic effect on stressed
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neurons. However, if APP over expression had an influence on neurogenesis one would
expect an increased neurogenesis, especially in younger, Aß pre-depositing mice. In vitro
experiments confronting precursor cultures with Aß are equally controversial: One study
found Aß42 to be toxic to human neural precursor cells and inhibit migration 174, another
study found that Aß42 provokes increased differentiation towards the neuronal cell fate, but
had no effect on proliferation or apoptosis 177.
Neurogenesis depends on an angiogenic niche and is located in close proximity to the
vasculature 26. Disturbance of the niche may interfere with stem cell behavior. Aß deposition
in the vasculature could induce such a disturbance, either through the loss of vascular cells 178,
which provide growth factors, or through an accumulation of activated microglia, which
influence neurogenesis through the expression of cytokines. Indeed, deficits in the brain
vasculature of an AD mouse model increases with progressive age and Aß deposition 179. A
similar disturbance of the neurogenic/angiogenic niche by microglia activation and/or spatial
disruption has been observed in irradiated mice 30,49. There are only few mouse models for
CAA available 178, and the impact on neurogenesis has not been investigated.
2.4.2. Angiogenesis in the AD brain
Neurogenesis in the vascular niche is regulated by the same growth factors angiogenesis
depends on. Vascular injury, hypoxia and inflammation promote angiogenesis, which is
stimulated by growth factors like VEGF and FGF-2, but also inflammatory factors like
histamine. In AD patients increased CSF levels of VEGF were measured 180, which arguable
might lead to the increased neurogenesis found in AD patients. In vitro, Aß stimulates
angiogenesis via an FGF-2 dependent mechanism 181. Interestingly, anti-histamines, lipid
lowering statins, and some non-steroidal anti-inflammatory drugs, which all suppress
angiogenic activity, reduce the risk of AD. Some authors argue that this injury induced
angiogenesis results in increased secretion of Aß by these activated endothelial cells, and
therefore plays an important role in Aß deposition 182. Considering that neurogenesis too is
altered by vascular injury and angiogenic reactions, its importance for AD might be wider
than previously expected. The direct effect of anti-angiogenic drugs on neurogenesis has not
been directly tested. However, the possibility that these drugs also lower neurogenesis has to
be considered, and if neurogenesis in AD is abnormally high, a drug-induced down regulation
might be part of the beneficial effect of these drugs on AD patients. Lipid lowering statins
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reduce the risk of AD and were also found to inhibit angiogenesis 183. Cdk-5, a kinase
involved in cell cycle regulation is inhibited by statins and over expression of Cdk-5 has been
shown to induce tau phosphorylation and cell death in neurons. In contrast it increases
proliferation in undifferentiated precursor cells 184. Thus angiostatin might block neurogenesis
through this mechanism. Histamine promotes angiogenesis in a mechanism parallel to VEGF
185, but its influence on neurogenesis is not known. The inflammatory response involves
factors for positive and negative regulation of neurogenesis and is discussed in the next
paragraph.
Interestingly, vascular density in the brains of AD patients or AD mouse models was found to
be either unaltered or lower than in age matching controls 179,186,187. In the mouse model
angiogenesis was found to be impaired despite an up regulation of angiogenic factors and
before Aß deposition was detected 188. Therefore, neurogenesis might be stimulated by a
disturbed vascular biology/angiogenesis including the secretion of angiogenic proliferative.
2.4.3. Inflammatory factors and neurogenesis
AD is accompanied by a profound inflammatory response. Numerous inflammatory and pro-
inflammatory factors such as complement, cytokines and acute phase reactants are up
regulated in the vicinity of Aß and accumulate in the Aß plaque 189. The neurogenic reaction
to local inflammation has only been studied in few cases, and the abundance and complexity
of actions of the released paracrine factors make it impossible to attribute the neuro-
inflammatory response as exclusively benign or detrimental to neurogenesis. Pro-
inflammatory cytokines are ligands of receptors on astrocytes and microglia, triggering the
expression of a cascade of inflammatory cytokines in the CNS. TNF-α induces expression of
IL-1 and IL-6, while IL-1 promotes growth factor and neurotrophin expression, IL-6 blocks
IL-1 and TNF-α transcription 190. IL-6 has also been studied in its effect on neurogenesis; in
transgenic mice with chronic expression of IL-6 in astrocytes, neurogenesis is strongly
reduced 50. Systemic injection of LPS induces a neuroinflammatory response resulting in a
decrease of neurogenesis, but administration of anti-inflammatory drugs or inhibition of
microglia activation prevents LPS induced down regulation of neurogenesis 49,191. An in vitro
experiment co-culturing neural stem cells with activated microglia found the same result, and
isolated exposure of neural stem cells to selected cytokines resulted in reduced neurogenesis
by IL-6 and TNF-α, but not by INF-γ or IL-1ß 49. Further evidence suggests that TNF-α acts
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upstream of IL-6 and that IL-6 can activate NOTCH expression through the IL-6R/gp130
receptor complex 49. Gp130 signaling and NOTCH expression has been shown to be
important in maintaining neural stem cells in an undifferentiated state 53. Alternatively, IL-6
expression concomitant to an inflammatory response is able to activate hormone production
of the HPA-axis and increase corticosterone levels in the plasma 192, leading to higher
corticosteroid levels in AD patients 193. Anti-inflammatory drugs were found to lower the risk
of AD 194,195. Most of these drugs block the pathway leading to the expression of IL-6 and it
could be argued, that a lower risk of AD is related to better functioning neurogenesis.
IL-1ß is another pro-inflammatory cytokine that is up-regulated in the AD brain 196. It
promotes the inflammatory reaction by increasing expression of IL-1, IL-6 and TNF-α and
proliferation of astrocytes and microglia 197. However, it is also involved in brain repair by
stimulating IGF-1 and helps to initiate angiogenesis 198,199. It might therefore protect neural
stem cells from other detrimental effects of inflammation and even promote proliferation.
TNF-α is the most pivotal of the cytokines, it may either be neurotoxic or neurotrophic, but it
is also central in promoting the inflammatory response 200. It is highly expressed in the
embryonic brain and in vitro it induces proliferation in primary astrocytes and glioma cells 201
or drives neuronal differentiation in neuroblastoma cells 202 and stimulates synthesis of NGF
and BDNF 203. However, high concentrations of TNF-α are toxic to neurons in vitro 204, it
induces the release of NO and glutamate 204,205 and disturbs electrophysiological membrane
properties 206. NO has been identified to promote neuronal differentiation of neuronal
precursor cells, and might be the mediator through which TNF-α interacts with neurogenesis
207. The cytokines described here trigger the release of other cytokines from glia cells and
neurons. Besides IL-6, Il-1 and TNF-α, IL-2, IL-3, IL-4, IL-8, IL-10, IL-12, IFN-α, IFN-ß,
IFN-γ, TNF-ß and TGF-ß have been found in the AD brain 196. Only few of the detailed
interactions and regulative mechanisms of this inflammatory reaction and neurogenesis have
been investigated. Despite first results that inflammation has an inhibiting effect on
neurogenesis 49, more detailed experiments about the impact of Aß induced inflammation on
neurogenesis are needed to understand the interactions of these brain processes.
2.4.4. Loss of neurotransmitter affects neurogenesis
AD is accompanied by a striking neuron loss within some major neurotransmitter systems.
Most prominent is the decline of ACh neurons in the nucleus basalis of Meynert, but there are
23
also deficits of noradrenergic, serotonergic and dopaminergic neurons. All of these
neurotransmitter systems have been related to a positive control of neurogenesis and their loss
is linked to memory deficits 54,55,208. Cholinesterase inhibitors are among the few drugs
countering AD symptoms and known to ameliorate the AD related memory deficits. The loss
of cholinergic neurons has been shown to have a negative effect on neural precursor
proliferation, and the accompanying memory deficits may be related to the resulting decline
of neurogenesis 55.
The loss of dopaminergic neurons is a prominent feature of Parkinson’s disease, but it is also
found in AD and is related to memory impairments 209. Moreover, Dopamine is an important
regulator of neurogenesis during ontogenesis and it is therefore no surprise that in the adult
neurogenesis is dependent on dopamine as well 54.
Serotonin is not only involved in memory but also mostly known for an involvement in mood
disorders such as depression. The loss of serotonergic input may lead to the mood disorders
associated with AD 210. Several links between depression and a low level of neurogenesis have
been made, but it is unclear to date, which is the cause and which the effect. Neurogenesis and
memory function is generally enhanced by selective serotonin uptake inhibitors 58. And
functional imaging and behavioral tests show impaired hippocampal function and decreased
neurogenesis in depressed patients 211. Taken together, the input of neurotransmitters is of
great importance for adult neurogenesis, memory and mood. The loss of these neurons and/or
disruption of the balance of neurotransmitter-release is likely to affect neurogenesis.
2.4.5. Influence of presenilin on stem cell biology
Although mutated presenilin (PS) is only accountable for a small percentage of AD cases, the
behavior of non mutated PS might be altered by other factors involved in AD. PS is involved
in the gamma secretase cleavage of APP processing 212. Interestingly presenilin is involved in
the processing of both APP and the notch receptor, producing an intracellular domain of the
receptor that influences gene expression in the nucleus of the cell. In the ectodermal tissue of
developing mesozoans binding and processing of Notch results in a suppression of the
neuronal phenotype and is essential in mammals for the maintenance of the stem cell
population 52. Indeed, PS knock out mice are perinataly lethal and conditional ablation of PS
in the adult forebrain or mutated PS results in impairments in neurogenesis and memory 213-215.
In contrast, over expression of PS results in increased neurogenesis 216.
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2.4.6. Aß induces sprouting on growing axons
Close vicinity of axons to Aß plaques promotes axonal growth and the formation of distrophic
boutons 217,218. These abnormally sprouting axons form distrophic synaptic boutons around Aß
deposits in the neuropil or vasculature, even if that particular cell does normally not innervate
this area. Neurogenesis produces maturing neurons in the GCL that grow axons to the CA3
area and dendrites into the ML. Because the hippocampus is strongly burdened by Aß plaques
in the AD brain, there is a strong possibility, that these growing processes are negatively
influenced or misguided by the plaques close by. This would strongly impair the function of
neurogenesis by inhibiting the correct connection to the existing network.
2.4.7. Hematopoietic stem cells in the AD brain
Hematopoietic stem cells from the bone marrow can be released to the blood stream and
participate in angiogenesis 219. Moreover if isolated and transplanted into blastocysts these
cells are reported of being able to differentiate into mesenchymal, endodermal and
neuroectodermal like cells 220. Due to the chronic inflammation observed in AD, the blood
brain barrier is weekend and the amount of peripheral cells entering the brain parenchyma is
increased. Aß induced lesions and neuron loss raise the question if stem cells from the
periphery are able to participate in neurogenic repair mechanisms by trans-differentiating to
the neuronal lineage. Hematopoietic stem cells can be genetically marked and injected into
mice deprived of their hematopoietic stem cell population by irradiation. The injected stem
cells repopulate the bone marrow and reconstitute the blood system 221. Invasion of the brain
parenchyma by descendants of the hematopoietic lineage can be monitored effectively this
way. Most of the cells passing the blood brain barrier are macrophages and seem to form an
“exogenous” microglia population. However, there is some controversy if these cells can
trans-differentiate to the neuronal lineage. Trans-differentiation of bone marrow derived cells
into neurons, detected by co-expression with neuronal markers, has been observed in a variety
of neuronal tissues; the neocortex, cerebellum, spinal chord and dorsal ganglia 222-224.
However, the ability for trans-differentiation of hematopoetic cells has been challenged by in
vivo and in vitro experiments demonstrating that bone marrow derived cells spontaneously
fuse with endogenous neurons 225,226. Only one of the groups reporting neuronal trans-
differentiation included controls that exclude cell fusion and concluded that a small number of
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cells indeed turn into neurons 222. It is also unknown, why hematopoietic cells fuse with
neurons and what the function of such a fused cell is. However, if peripheral hematopoietic
stem cells participate in neuronal repair mechanisms, this would have broad implications, not
only for the ethiology and therapy of AD, but would also drastically alter our understanding
of how the brain and the peripheral organs interact.
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3.1. Abstract
Age-related changes in neurogenesis and its modulation by caloric restriction (CR) were
studied in C57BL/6 mice. To this end, bromodeoxyuridine (BrdU) labeling was used to assess
neuronal and glial precursor proliferation and survival in the granular cell layer (GCL) and the
hilus of the dentate gyrus of 2-, 12-, 18-, and 24-month-old mice. For both regions, we found
an age-dependent decrease in proliferation but not in survival of newborn cells. Interestingly,
the reduction in proliferation occurred between 2 and 18 months of age with no additional
decline between 18- and 24-month-old mice. Phenotyping of the newborn cells revealed a
decrease in the neuron fraction in the GCL between 2 and 12 months of age but not thereafter.
The majority of BrdU cells in the hilus colocalized with astrocytic but none with neuronal
markers. CR from 3 to 11 months of age had no effect on neurogenesis in the GCL, but had a
survival-promoting effect on newly generated glial cells in the hilus of the dentate gyrus. In
conclusion, C57BL/6 mice reveal a substantial reduction in neurogenesis in the dentate gyrus
until late adulthood with no further decline with aging. Long-term CR does not counteract this
age-related decline in neurogenesis but promotes survival of hilar glial cells.
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3.2. Introduction
The vast majority of cells in the CNS are generated during the embryonic and early postnatal
period, but new neurons are continuously added in selected regions of the mammalian brain 1-
5. Neurogenesis has been described in the subgranular layer of the dentate gyrus 3,6 and the
subventricular zone of the lateral ventricle 7-9. Newborn cells in the subgranular layer migrate
into the granule cell layer (GCL), where a portion differentiates into neurons, which then
extend axons to the CA3 region 10-12. Although the functional significance of this ongoing
neurogenesis in the dentate gyrus remains to be fully established, evidence has been provided
that newly produced neurons play an important role in learning and memory 13-15. Because a
decline of neurogenesis in the dentate gyrus has been reported with aging 5,16, a relationship
between the age-related decline in neurogenesis and age-dependent cognitive impairments
may be suggested 17.
In numerous rodent studies, caloric restriction (CR) has been shown to extend life span,
postpone the onset of age-related changes including brain aging, and maintain physiological
function at more youthful levels 18,19. Thus, it is tempting to speculate that CR may also
postpone the age-related decline in neurogenesis. Indeed, short-term CR has been reported to
increase neurogenesis in the dentate gyrus of young mice and rats 20,21.
The aim of the present study was to investigate the effects of aging and CR on neurogenesis
in the dentate gyrus of C57BL/6 mice. C57BL/6 mice were selected because this mouse strain
has become the most common background for genetically engineered mouse models of age-
related neurodegenerative diseases 22,23. Moreover, we have previously assessed age-related
changes in granule cell number in the dentate gyrus of this mouse strain 24 and thus have
provided a basis for the interpretation of age-related changes in neurogenesis in the dentate
gyrus of C57BL/6 mice.
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3.3. Materials and Methods
3.3.1. Animals
To study age-related changes in neurogenesis, 2-month-old (n = 11), 12-month-old (n = 13),
18-month-old (n = 11), and 24-month-old mice (n = 5) male C57BL/6 mice were used. Their
respective mean body weights were: 24.4, 31.5, 32.6, and 32.0 g (S.E.M. ± 0.7 to ± 1.3 g). To
examine the effects of the diet manipulation on aging, 11-month-old C57BL/6 mice ad
libitum (AL) fed (n = 13) and caloric restricted (n = 9) were used. Their respective mean body
weights were: AL fed, 31.3 ± 0.7 g; CR, 23.8 ± 0.5 g. CR was initiated at 10% at 14 weeks of
age, lowered to 25% at 15 weeks of age and was set at 40% from 16 weeks on 25. All mice had
been housed in standard cages in a colony maintained by the National Institute on Aging at
Harlan Sprague–Dawley (Indianapolis, IN).
3.3.2. BrdU labeling and cellular phenotyping
For labeling of newly generated cells mice were given daily single injections of
bromodeoxyuridine (BrdU; 50 µg/g body weight, i.p., Sigma) for five consecutive days. Half
of the mice of each age group were killed 2 h after the last BrdU injection to study
proliferation of dividing cells. The other half were killed 4 weeks later to study survival and
differentiation of newly produced cells. In 24-month-old mice, only the 4-week time-point
was examined. Mice were overdosed with pentobarbital and transcardially perfused with 4%
paraformaldehyde in PBS. Brains were removed and postfixed in the same fixative overnight
and then placed in 30% sucrose in PBS for 2 days. Brains were subsequently frozen in 2-
methylbutane at –25°C and serially sectioned on a freezing-sliding microtome at 40µm. For
detection of BrdU-positive cells, sections were pretreated as previously reported 5. Briefly,
sections were incubated in 50% formamide in 2 x SSC for 2 h at 65°C, followed by 10 min in
2 x SSC, 30 min in 2N HCl at 37°C and 10 min in 0.1M borate buffer. Sections were then
incubated in 0.08% H2O2, followed by 0.3% Triton X-100, and blocked in 5% rabbit serum,
all in TBS. Rat monoclonal antibody against BrdU (MAS250c; Accurate Ltd., Westbury, NY)
was diluted 1:1000 in TBS with 2% serum and 0.3% Triton X-100. Sections were then
incubated in biotinylated anti-mouse IgG followed by the avidin–biotin–peroxidase complex
solution (Vector Laboratories). Sections were reacted with 3,3-diaminobenzidine (0.08%,
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Sigma) and 0.03% hydrogen peroxide in PBS for 2 min, rinsed, dehydrated, cleared, and
coverslipped. To study the cellular phenotype of BrdU-labeled cells, double and triple
immunofluorescence stainings were performed with a combination of antibodies to BrdU (see
above), NeuN (mouse monoclonal, 1:1000, Chemicon, Temecula, CA) and S100  (rabbit
polyclonal, 1:2000, Swant, Bellinzona, Switzerland). The secondary antibodies were
Alexa488 goat anti-mouse IgG, Alexa568 goat anti-rat IgG and Alexa633 goat anti-rabbit IgG
(1:400, Molecular Probes). In case of high autofluorescence background, sections were
incubated in 70% ethanol/0.3% Sudan Black B (Merck, Darmstadt, Germany) and
coverslipped in mounting medium Vectashield (Vector Laboratories). Sections were analyzed
with a Confocal Laser Scanning Microscope LSM 510, inverted Axiovert 100M (Zeiss).
3.3.3. Stereological analysis
The total number of BrdU-positive cells in the GCL and hilus of the dentate gyrus was
estimated using a variant of the optical fractionator technique 26. Quantifications were
performed on systematic random series of every sixth coronal section throughout the entire
right dentate gyrus (12–16 fixed-frozen sections per animal). Cells were counted using a
100x, 1.3NA objective and an accurate three-dimensional stage movement coupled to a video-
microscopy system (Systems Planning and Analysis Inc., Alexandria, VA). The mean section
thickness was 17.9 ± 0.5µm. Cells touching the GCL were considered part of the GCL. To
avoid any artifacts at the section edges, cells falling in a 3µm guard height were ignored. The
sum of counted cells was multiplied by the reciprocal of the fraction of the brain region
sampled, resulting in the total number of BrdU-positive cells/region. Results were analyzed
using ANOVA with the help of the statistical software package SPSS 10.0.1. Data are
presented as the mean and S.E.M. Statistical significance was accepted as P < 0.05.
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3.4. Results
3.4.1. Aging and neurogenesis
To study the impact of aging on neurogenesis in the dentate gyrus, C57BL/6 mice of four age
groups (2-, 12-, 18-, and 24-month-old) were analyzed 2 h and 4 weeks after the last BrdU
injection. Two hours post-BrdU, cell proliferation was predominantly conferred to the
subgranular layer (Fig. 1A, C, and E). The BrdU-positive nuclei were often clustered in the
subgranular layer and exhibited variable shapes. In contrast, the majority of BrdU-labeled
cells 4 weeks after BrdU treatment were located mostly inside the GCL and revealed large
round nuclei (Fig. 1B, D, and F). Qualitative assessment indicated a robust increase in number
of BrdU-labeled cells in the 2-month-old mice when compared to older mice. The hilus of
both the 2-h post-BrdU and the 4-week post-BrdU groups revealed only few BrdU-positive
cells (Fig. 1). Their distribution appeared random and an age-related decrease was also
apparent.
Fig. 1. Age-dependent proliferation and survival of BrdU-labeled cells in the dentate gyrus. Mice received BrdU
injections on 5 consecutive days and were analyzed 2 h (A, C, and E) and 4 weeks (B, D, and F) later. Two
hours post-BrdU cells are predominantly aligned and clustered at the hilar-granule cell border (arrowheads in
A and C). BrdU-positive cells exhibit a variety of shapes (E). Four-week post-BrdU cells have partly migrated
into the GCL (arrows in B and D) and reveal large round nuclei with a chromatin structure similar to mature
granular cells (F). Note the dramatic decrease in BrdU-positive cells in 18-month-old mice (C and D) compared
to 2-month-old mice (A  and B ). Scale bars are 50  m (A – D) and 10  m (E  and F).
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Using stereological quantification, we observed an age dependent decrease in the number of
BrdU-labeled cells in the GCL (Fig. 2A) and the hilus (Fig. 2B) in both the 2 h and 4-week
post-BrdU groups. Overall, the hilus contained substantially less BrdU-positive cells than the
GCL. Two-way ANOVA for the two main factors age and post-BrdU time was performed
separately for the GCL and the hilus. To stabilize the variance in the age groups and to
achieve a normal distribution, a logarithmic transformation was applied. Results revealed
highly significant main effects for age and post-BrdU time for both regions (Table 1).
Subsequent Scheffé post hoc analysis revealed robust age-dependent decreases in BrdU-
positive nuclei up to 18 months of age in both the GCL and hilus. Interestingly, however, no
further significant decline in BrdU-positive cell number was detected between 18- and 24-
month-old mice.
Fig. 2. Stereological estimation of the total number of BrdU-positive cells in the dentate gyrus in aging C57BL/6
mice. The dentate gyrus was divided into the GCL (A) and the hilus (B), and these regions were analyzed
separately. Results revealed that 2 h and 4 weeks post-BrdU, there was an age-related decrease in the number of
newborn cells both in the GCL and in the hilus, *p < 0.01. Interestingly, however, in both regions, no further
decline was seen between 18- and 24-month-old mice.
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To address the question of whether proliferation or survival of BrdU-labeled cells was
decreased with aging, the number of BrdU-labeled cells 4 weeks post-BrdU was expressed as
a ratio of the number 2 h post-BrdU. Results indicated an increase of the ratio with advancing
age in both the GCL and hilus (27 and 44% at 2 months, 46 and 69% at 12 months, 55 and
53% at 18 months, respectively), which demonstrates that the age-related decline in BrdU-
positive cells is solely attributable to an age-dependent decrease in proliferation but not
survival of newborn cells.
Table 1 Statistical parameters of two-way ANOVA analysis for number of BrdU-positive cells in the dentate
gyrus. GCL: granular cell layer; d.f.: degrees of freedom.
Table 2 Phenotype of BrdU-positive cells in the GCL and in the hilus of 2-, 12-, 18-, and 24-month-old mice, 4
weeks after the last BrdU injection. BrdU-positive cells were labeled with markers for neurons (NeuN) and
astrocytes (S100ß). Number of analyzed cells (in parenthesis) and percent of BrdU-colabeled cells are indicated.
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To phenotype the newly generated cells, immunofluorescence triplelabeling for BrdU, the
neuronal marker NeuN, and the astrocytic marker S100ß was performed (Fig. 3). The dentate
gyrus of three randomly chosen animals of each age group were analyzed with confocal
microscopy. In the GCL, we found a considerable decrease in the fraction of BrdU/NeuN-
colabeled cells between the 2- and 12-month-old mouse groups, with no further decline
thereafter (Table 2). Interestingly, when the percentage of BrdU/NeuN-positve cells (Table 2)
was multiplied by the survival ratios of BrdU-labeled cells of the corresponding age group
(see above), neurons accounted for 18% of the surviving BrdU-positive cells in the GCL of all
age groups. In contrast, an analogous analysis for BrdU/S100 –labeled cells showed that the
ratio of cells committed to an astrocytic lineage tended to increase with age (2% at 2 months,
7% at 12 months, and 12% at 18 months). In the hilus, no BrdU-labeled neurons were found
in any age group. The majority of newly produced cells in this region colocalized with the
astrocytic marker S100ß (Table 2).
Fig. 3. Cellular phenotyping of BrdU-positive cells. BrdU immunofluorescence (red) was combined with the
neuronal marker NeuN (green) and the astrocytic marker S100ß (blue) and colocalization was assessed with
confocal scanning microscopy. In 2-month-old mice, 4 weeks post-BrdU, the majority of the BrdU-labeled cells
were positive for the neuronal marker NeuN (A). Note the variety of BrdU-labeling, ranging from dense stained
neurons (arrow) to only partly labeled neurons (arrowhead), indicating a dilution effect of repeated stem cell
divisions. In contrast to the GCL, BrdU-labeled cells in the hilus colocalized most frequently with the astrocytic
marker S100ß in all age groups (arrowhead in B; shown is a 18-month-old mouse 4 weeks post-BrdU). The
insert in (B) represents single confocal sections of BrdU and S100ß. Scale bar is 20 µm.
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3.4.2. Caloric restriction and neurogenesis
The effect of CR on neurogenesis in the mouse dentate gyrus was studied in 11-month-old
mice. Qualitative analysis of the GCL revealed no effect of CR on the number of BrdU-
labeled cells in either the 2-h post-BrdU or the 4-week post-BrdU group (Fig. 4). In contrast,
4 weeks post-BrdU, newborn cells in the hilus were markedly increased in CR mice compared
to AL-fed mice (Fig. 4D versus 4B). Stereological quantification confirmed this qualitative
assessment and revealed that CR affected only the survival of BrdU-labeled cells in the hilus
but not in the GCL (Fig. 5). Consistently, two-way ANOVA revealed that the factor post-
BrdU time was highly significant for both brain regions, but no significance was found for the
factor AL/CR (Table 1). However, in the hilus, a significant interaction between AL/CR and
post-BrdU time was found (Table 1). Scheffé post hoc analysis showed that CR mice had
significantly more newborn hilar cells in the 4-week post-BrdU group (P = 0.001) but not in
the 2-h post-BrdU group (P = 0.78) compared to AL mice. Cellular phenotyping of
BrdU/NeuN-positive cells in the GCL revealed similar percentages of colocalization between
the two groups (AL = 49%, CR = 37%, four randomly chosen animals of each group
analyzed; 80 cells phenotyped per group). Again no BrdU/NeuN colabeling was found in the
hilus (not shown), suggesting that the increased survival of newborn hilar cells is the result of
an increased survival of glial cells in CR mice.
Fig. 4. Proliferation and survival of BrdU-labeled cells in the dentate gyrus of ad libitum-fed (AL) and caloric-
restricted (CR) mice. Eleven months old mice were killed 2 h (A and C) or 4 weeks (B and D) after the last BrdU
injection. No qualitative difference was found when number of newborn cells in the GCL of CR mice (C and D)
were compared to AL-fed mice (A and B). In contrast, the survival of BrdU-positive cells in the hilus was
increased in the CR mice (arrowheads in D) when compared to AL-fed mice. Scale bar is 50 µm.
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3.5. Discussion
In the present study, we have investigated the impact of aging and CR on neurogenesis in the
dentate gyrus of C57BL/6 mice. Proliferation of BrdU-positive cells was assessed 2 h post-
BrdU, whereas a 4-week survival period was used to examine cell survival and
differentiation.
3.5.1. Age-related changes in cell proliferation
Our stereological findings of a significant age-dependent decline in neurogenesis in the GCL
parallel previous findings in mice 27 and rats 5,17,28,29. The reduction of neurogenesis with aging
was mainly caused by an age-related decrease in progenitor cell proliferation, whereas cell
survival did not change with aging. In addition, the phenotypic differentiation of newborn
cells into neurons decreased with age. Interestingly, all these changes occurred mainly
between 2 and 12 months of age, with some additional decline until 18 months of age, but no
further reduction in neurogenesis thereafter. In previous studies, the impact of aging on
neurogenesis was examined in only two or three age groups, and thus the progression of the
decline in neurogenesis could not be examined in detail 5,17,27,28. Thus, the current findings
would suggest greater functional significance of neurogenesis in younger mice with less
impact on those approaching their median life span.
Fig. 5. Stereological estimation of the total number of BrdU-positive cells in the dentate gyrus of caloric-
restricted (CR) mice. CR had no effect on the total number of newborn cells in the GCL neither 2 h nor 4 weeks
post-BrdU in comparison to ad libitum (AL) fed mice (A). Interestingly, in the hilus, where no BrdU/NeuN
colabeled cells were detected, CR did not influence proliferation (2 h post-BrdU) but increased significantly
s u r v i v a l  ( 4  w e e k s  p o s t - B r d U )  o f  n e w b o r n  c e l l s  ( B ) ,  P < 0.05 .
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The decrease in progenitor cell proliferation with aging may be due to a decline in the pool of
neuronal progenitors 30 or a lengthening of the cell cycle with aging 31. The decrease in
neurogenesis has also been explained by an age-related increase in stress-induced
glucocorticoids 32,33. Indeed, adrenalectomized rats show a markedly higher proliferation of
neural precursors and no age-related decrease in neurogenesi 17. Furthermore, physical
activity, which has been shown to increase neurogenesis 13, declines in an age-dependent
manner in rodents, including C57BL/6 mice 34,35. Unfortunately, none of the studies examined
whether such changes also decline until late adulthood but then remain stable in old age.
A relationship between the age-related decline in neurogenesis and age-dependent cognitive
impairments has been suggested 17. Thus, it could be speculated that the age-related reduction
in neurogenesis and/or decreased neuronal turnover may underlie learning and memory
deficits with aging in mice. However, we have previously reported that C57BL/6 mice are
relatively resistant to age-related decline in spatial memory performance and show either no
significant (C57BL/6J) or only very subtle (C57BL/6Nnia) cognitive changes with aging in
hippocampus-dependent tasks 22,24. Although we cannot exclude that age-related changes in
neurogenesis contribute to cognitive changes in hippocampus-dependent tasks, the present
results do not support this view. In future studies, it will be interesting to analyze age-related
changes in neurogenesis in other inbred mouse strains that reveal more robust age-related
cognitive changes such as the 129 mouse strain 22,24.
In the hilar region of the DG, neurogenesis was not apparent, and the majority of the BrdU-
labeled cells revealed an astrocytic phenotype. This finding is consistent with previous
studies, however, a smaller percentage of BrdU-positive cells with an astrocytic phenotype
has been reported 36,37. Interestingly, in the present study, we found a significant age-related
decrease in the proliferation of such hilar astrocytes. Similar qualitative assessment in rats
also revealed modest age-related decrease in astrocyte proliferation 5,28. These observations
suggest that aging decreases the astrocyte turnover in the DG because in previous studies we
found no age-related change in total number of astrocytes in male C57BL/6J mice 38,39.
3.5.2. Caloric restriction and neurogenesis
No difference in either proliferation, nor survival and differentiation of newly generated cells
was observed in the GCL of CR compared to AL mice. Many studies have reported how CR
in mice can attenuate several age-related physiological changes 18,40,41, thus, an effect of CR on
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neurogenesis may have been expected. Indeed, in two previous studies, an increase in
neurogenesis in adult CR rats and mice has been reported 20,21. The different outcome in the
current study may be due to differences in methodology. First, the feeding schedule differs
among the studies, in that in the previous studies CR was imposed by providing the animals
with food on alternate days. One speculative explanation would be that these animals are
exploring their cage for food on the days maintained on diet and therefore their level of
physical activity is increased compared to our mice. This in turn could increase their
neurogenesis, as shown for mice with increased physical activity 13. Second, the previous
studies were performed with 6-month-old animals that have been food restricted for only 3
months, while in the present study 11-month-old mice that have been on DR for 8 months
have been used. Third, the previous studies did either not differentiate between hilus and GCL
20 or did not phenotype BrdU-positive cells in AL-fed mice 21 making a direct comparison
difficult.
Surprisingly, in contrast to the lack of CR on neurogenesis, we found an increased survival of
glial cells in the hilus of CR mice compared to in AL-fed mice. This increase might occur
because of a mild metabolic stress that undernourished mice are afflicted with 18,42. In a
transgenic mouse model of Alzheimer’s disease, we have previously reported an increase in
glial proliferation in vicinity of amyloid plaques that may be considered as another form of
stress although it may simply be viewed as a response to injury 43,44.
In summary, our findings demonstrate that neurogenesis in the dentate gyrus of C57BL/6
mice decreases with advancing age and reaches a plateau around 18 months of age and
remains stable thereafter. CR has no significant effect on the number of newly generated
hippocampal neurons in adult mice but may increase the survival of glial precursors in the
hilus.
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4.1. Abstract
Alzheimer’s disease (AD) patients have a depletion of hippocampal neurons with
accompanying deficits in learning and memory, and mouse models forming ß-amyloid (Aß)
deposits show hippocampal deficits as well. In neither case is it known whether alterations in
function are accompanied by alterations in neural stem cell biology and/or hippocampal
neurogenesis. Here, hippocampal neurogenesis was investigated in amyloid precursor protein
(APP) transgenic mice that develop abundant Aß deposition with aging. Neurogenesis in adult
APP23 mice prior to Aß deposition showed no clear difference relative to age-matched
controls but aged amyloid-depositing mice showed significant increases in neural precursor
proliferation and neurogenesis. To further investigate how Aß affects neural stem cell
biology, nestin-positive neural stem cells were analyzed in APPPS1 mice, a transgenic mouse
model with early and aggressive cerebral amyloidosis. Results revealed a decrease in
quiescent astrocyte-like stem cells, but not transient amplifying progenitor cells. This was
accompanied by an aberrant morphologic reaction of hippocampal neural stem cells towards
Aß-deposits. Our results provide evidence for a disruption of neural stem cell biology in an
amyloidogenic environment with a concomitant stimulation of neurogenesis.
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4.2. Introduction
Neurogenesis in the mammalian brain continues through adulthood and into old age primarily
in the subventricular zone (SVZ) of the lateral ventricles, the olfactory bulb and the granular
cell layer (GCL) of the hippocampus 1-3. GCL neurons are generated in high numbers in
young animals and despite a significant decrease with progressive age, neurogenesis
continues until senescence 4,5. The function of neurogenesis in the hippocampus remains
elusive, but growing evidence suggests its importantance for certain memory tasks that are
also strongly affected in Alzheimer’s disease (AD) 2,6.
The neuropathological characterization of AD involves a progressive deposition of ß-amyloid
(Aß) protein in the brain parenchyma, often accompanied by Aß deposition in cerebral blood
vessels with an accompanying vascular angiopathy 7,8. It has been suggested that other
hallmarks of AD, i.e. an increased inflammatory response, neurofibrillary tangles, dystrophic
neurites, neuron loss or cognitive deficits are triggered by the accumulation of Aß and that
this combined insult influences the cognitive outcome 9.
The hippocampus is one of the regions of the AD brain most heavily burdened with amyloid
plaque and is also one of the few locations in the adult brain where neurogenesis continues
throughout adult life. Several attributes of adult hippocampal neurogenesis suggest that
amyloid deposition may influence neurogenesis. Proliferative amplification of neural
progenitor cells occurs within the microvascular niche 10, an area prone to amyloidogenesis
and affected in virtually all AD cases 11-15. Numerous growth factors are known to be up-
regulated in vicinity of amyloid plaques 16-18 and the same growth factors are also known to be
potent modulators of neural stem cell activity 19-24. Conversely, inflammation that
accompanies amyloid deposition 25 may negatively impact neurogenesis given the potent
down-regulation of neurogenesis observed in pro-inflammatory environments 26,27.
In the present study, two amyloid precursor protein (APP) transgenic mouse models were
used to evaluate the potential impact of Aß deposition on neural stem cell biology. Our results
provide evidence for a disruption of neural stem cell biology in the amyloidogenic brain and
an accompanying increase in neurogenesis.
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4.3. Materials and Methods
4.3.1. Animals
In a first experiment adult (5 month-old) and aged (25 month-old) female APP23 transgenic
mice and corresponding non-transgenic control mice were used 28. APP23 mice express
KM670/671NL mutated human APP under a murine Thy-1 promoter element. Mice have
been generated on a B6D2 background and in the following, have been backcrossed with B6
mice for more than ten generations. In a second experiment APPPS1 transgenic mice
expressing both KM670/671NL mutated human APP and L166P mutated human PS1 under
the same Thy-1 promoter element 29 were crossed with transgenic mice expressing enhanced
green fluorescence protein (GFP) under a CNS-specific nestin promoter element 30. APPPS1
mice have been generated on a pure B6 background, while Nestin-GFP transgenic mice have
been generated on a B6D2 background and were backcrossed to B6 for at least three
generations. Adult (8 month-old) female GFP+/APPPS1+ (GFP-APPPS1) and age-matched
littermate GFP+/APPPS1– (GFP-wt) control mice were used. All experimental procedures
were in accordance with the local veterinary office regulations.
4.3.2. BrdU treatment
5-Bromo-2-deoxyuridine (BrdU) was obtained from Sigma (Taufkirchen, Germany). During
the first seven days of the experiment animals received daily i.p. injections of 50 µg BrdU/g
body weight at a concentration of 10 mg/ml in 0.9% NaCl. Mice were sacrificed three weeks
after the last BrdU injection.
4.3.3. Tissue preparation
Mice were anesthetized with an overdose of 0.8% ketamine and 1% xylazine in 0.9% NaCl,
transcardially perfused with PBS followed by ice-cold 4% paraformaldehyde (PFA) in 0.1M
PBS. Brains were removed and postfixed at 4°C in 4% PFA, dehydrated in 30% sucrose, and
frozen. Coronal serial 40µm sections were cut with a microtome and collected in
cryoprotectant (30% glycerol, 45% ethylene glycol in PBS) and stored at –20°C until use.
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4.3.4. Immunohistochemistry
Free-floating sections were processed for immunohistochemistry as described elsewhere 10,31.
Briefly, sections were washed in TBS and blocked with 3% goat or donkey serum (Vector
Laboratories Inc., Burlingame, CA) in 0.3% Triton-X-100 (Fisher, Fair Lawn, NJ). The
sections were incubated overnight with primary antibodies at 4°C in 2% serum and 0.3%
Triton-X-100, washed three times with TBS and incubated for 3 hours with biotin-conjugated
secondary antibodies. After repeated TBS washing, sections were stained by complexing with
avidin-biotin and DAB or SG blue (Vectastain ABC elite kit; Vector Laboratories). Sections
were mounted on pre-cleaned glass microscope slides (Superfrost® Plus; Langenbrinck,
Teningen, Germany), dehydrated with an alcohol series, cleared in xylene and coverslipped in
a xylene soluble mounting medium (Pertex®; medite GmbH, Burgdorf, Germany).
For immunofluorescence, a similar protocol was followed but with fluorophore coupled
secondary antibodies. After the 3 hours incubation time with secondary antibodies, sections
were repeatedly washed in TBS, mounted and coverslipped in polyvinyl alcohol with 2,5%
DABCO (Sigma) or Vectashield® (Vector Laboratories) for GFP fluorescence.
Primary antibodies were used at the following concentrations: rat anti-BrdU (1:1000;
Accurate, Westbury, NY), goat anti-doublecortin (1:500; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), mouse anti-NeuN (1:1000; Chemicon Int., Temecula, CA), guinea pig anti-
GFAP (1:1000; Advanced ImmunoChemical, Inc., Long Beach, CA), rabbit anti-S100ß
(1:2000; Swant, Bellinzona, Switzerland) and rabbit anti-Iba-1 (Wako Chemicals, Neuss,
Germany). As secondary antibodies Biotin-SP, Cy5, Cy3, (Vector Laboratories) or Alexa 488,
Alexa 568 (Molecular Probes, Inc., Eugene, OR) conjugated goat or donkey IgG at a dilution
of 1:500 were used.
For BrdU antigen retrieval, sections were treated for 30 minutes with 2 M HCl at 37°C
followed by repeated washing with TBS. For immunofluorescence co-labeling experiments
with BrdU, sections were first stained for NeuN and GFAP, then fixed for 10 minutes in 4%
PFA followed by antigen retrieval processing and staining for BrdU.
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Histochemistry
Fibrillar Aß was visualized by staining free floating sections with 0.005% thioflavine S
(Sigma) for 1 min. Alternatively, mounted sections were incubated in 0.5% Congo red
(Sigma) in NaCl-saturated 80% ethanol.
Quantification of cell number and plaque load
For the stereological analysis of the total number of BrdU and DCX positive cells in the GCL
of APP23 mice, every sixth section through the hippocampus was immunohistochemicaly
stained and BrdU and DCX-positive cell numbers were estimated under light microscopy
using the ‘Optical Fractionator’ probe of Microbrightfield Stereo Investigator software (MSI;
MicroBrightField, Williston, VT). Cells were included in the analysis, if located inside or
within one cell diameter of the GCL.
For phenotyping of BrdU-positive cells, triple immunofluorescence was used using anti-
BrdU, anti-NeuN, and anti-GFAP antibodies. Cells were scored using a Zeiss 510 Meta
confocal microscope (Jena, Germany). Careful optical sectioning in the z-plane was used to
avoid scoring closely juxtaposed cells as double-positive 32. In 5 month-old APP23 mice, one
hundred BrdU positive cells per animal were examined, while in 25 month-old animals,
where BrdU labeling was often very low 4, 40 to 100 cells per animal were analyzed. The total
number of BrdU-positive cells that co-labeled with a specific lineage marker was estimated
by multiplying the lineage positive percentage by the total number of BrdU positive cells in
the GCL as stereologically estimated.
The number of stem cells in the GCL of GFP-APPPS1 and GFP-wt mice was estimated using
a variant of the optical fractionater technique as previously described 4. Every sixth section
throughout the entire hippocampus was stained immunohistochemically for GFP and analyzed
under the light microscope. The total number of cells was estimated by multiplying the
counted cell number with the reciprocal of fraction of the sampled region. GFP-positive cells
were classified as quiescent astrocyte-like or transient amplifying cells, if the orientation of
the dendritic processes were either perpendicular or horizontal, respectively, and if the cell
body was located in the subgranular zone 33.
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Amyloid load was estimated on every sixth section through the entire dentate gyrus of the
hippocampus using the ‘Area Fraction Fractionator’ probe of MSI software using a similar
protocol as previously described 34. The region was determined according to a mouse brain
atlas 35.
4.3.5. Statistical analysis
Statistical analysis was performed using ANOVA (Statview 5.0 for Macintosh). Throughout
the paper the mean ± standard error of the mean is indicated. Statistical significance was
accepted as p < 0.05.
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4.4. Results
4.4.1. Increased proliferation in aged APP23 mice
The incorporation of BrdU in the S-phase of mitotic cell division was used to monitor
proliferative activity in the GCL. The effect of age (5 mo vs. 25 mo) and genotype (wild type
vs. transgenic mice) on the number of newly generated cells in the dentate GCL of APP23
mice was estimated using unbiased stereological methods (Fig. 1). ANOVA revealed a
significant effect of age [F(1,20) = 11.16; p < 0.01] and an age and genotype interaction
[F(1,20) = 4.89; p < 0.05; n=6/group]. In young 5 mo-old mice there was no statistical
difference between transgenic mice and wild type mice, although transgenic mice appeared to
have less BrdU-positive cells. In aged 25 mo-old mice, a significantly higher number of BrdU
positive cells was found in the GCL of transgenic compared to control mice [t(10) = 4.95; p <
0.001], reaching almost the level of adult 5-mo-old APP23 mice (Fig. 1).
Fig. 1: BrdU-positive cells in the GCL. Three weeks after BrdU injections cell proliferation in the GCL was
evaluated in adult and aged APP23 mice and littermate control mice by stereological estimation of the number
of BrdU positive cells in the GCL (n=6/group). (A) In 5 mo-old APP23 mice no difference was found (6
mice/group). (B) In aged 25 mo-old APP23 mice, the number of BrdU positive cells was significantly increased
compared to wild type (WT) mice (6 mice/group; * p < 0.001). (C, D) BrdU positive cells (closed arrows) in
aged 25 mo-old WT (C) and APP23 (D) mice were found close to the SGZ of the dentate gyrus. In aged APP23
mice proliferating microglia (open arrows) were often found in the periphery of amyloid plaques (asterisk), but
t h i s  w a s  r a r e l y  f o u n d  w i t h i n  t h e  G C L .  S c a l e  b a r :  5 0 µ m .
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Stereological estimation of the amyloid load in the dentate gyrus of 25 mo-old mice was 14.0
± 1.9% while no amyloid deposition was found in the 5 mo-old APP23 mice, demonstrating
that the amyloidogenic environment of aged APP23 mice was accompanied by increased
proliferative activity in the dentate gyrus.
4.4.2. Increased neurogenesis in aged APP23 mice
To determine whether this increased proliferation reflects neurogenesis, BrdU labeling was
combined with confocal microscopy and fluorescent multiple labeling for the neuronal marker
NeuN and the glial marker GFAP. In 5 mo-old APP23 mice no difference in the total number
of BrdU and NeuN co-labeled cells was found (Fig. 2). There was also no difference in the
fractions of BrdU positive cells co-labeling with NeuN in transgenic and wild type mice
(71.4% ± 5.3% and 67.0% ± 5.9%, respectively; p > 0.05). In contrast, aged APP23 revealed a
six fold higher number of total newborn neurons compared to wild type mice [t(10) = 2.73; p
< 0.05] (Fig. 2). The fraction of BrdU cells expressing NeuN also appeared greater however
did not reach significance in aged APP23 mice compared to wild type animals (10.9% ± 4.0%
vs. 3.7% ± 0.8%; p > 0.05).
Fig. 2: Neurogenesis in the GCL. Estimated numbers of BrdU-positive cells co-labeled with the neuronal marker
NeuN in adult and aged wild type (WT) and APP23 mice (6 mice/group). (A) In 5 mo-old mice no difference was
found in the number of newly generated neurons between WT and APP23 mice, while (B) in 25 mo-old APP23
mice a significantly higher number of BrdU/NeuN double positive cells was found compared to WT (* p < 0.05).
(C) Capture of multiple confocal images in the Z-dimension allows the evaluation of the co-localization of
different markers in all 3 dimensions. Green: NeuN; Blue: BrdU; Red: GFAP; Scale bar: 10µm.
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The percentage of BrdU positive cells co-labeled for GFAP was low in both 5 mo-old (0.9% ±
0.6% and 2.4% ± 1.2% in wild type and transgenic, respectively) and 25 mo-old animals
(1.4% ± 0.9% and 4.3% ± 1.3% in wild type and transgenic, respectively) resulting in very
few BrdU-labeled astrocytes in the GCL. In 5 mo-old APP23 animals no significant
difference was observed in newborn glia between transgenic and wild type mice (6.5 ± 3.6
and 5.1 ± 3.3 newborn astrocytes per GCL respectively), while in 25 mo-old animals
significantly more newborn glia cells were found in transgenic compared to wild type control
mice (12.3 ± 3.5 vs. 1.3 ± 1.0, newborn astrocytes per GCL respectively; p < 0.05).
Fig. 3: DCX-positive immature neurons in the GCL. Numbers of immature neurons in the GCL were estimated
with unbiased stereological methods (A) In adult 5 mo-old wild type (WT) mice the pool of DCX positive cells
was smaller compared to APP23 mice (* p < 0.05). (B) In aged 25 mo-old mice the population of immature
neurons was significantly increased in APP23 mice (6 mice/group; * p < 0.005).  This increase was most
pronounced in the caudal pole of the dentate gyrus. (C-F) Representative micrographs of DCX positive cells in
the GCL of 5 mo-old WT (C), 5 mo-old APP23 (D), 25 mo-old WT (E) and 25 mo-old APP23 mice (F). Astrisks
indicate amyloid plaques. Scale bar: 50µm.
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4.4.3. Immature doublecortin-positive cells are also increased in aged APP23 mice
Because the incorporation of BrdU into dividing cells takes place after systemic
administration of BrdU, it cannot be excluded that Aß induced changes in the vascular system
influence the uptake of BrdU. Thus, we sought to confirm our results with an additional
marker of neurogenesis. Neuroblasts committed to the neuronal lineage express doublecortin
(DCX) during their last divisions but subsequently down-regulate DCX as NeuN is up-
regulated during neuronal maturation 36,37. DCX is therefore an excellent marker to monitor
the abundance of immature neurons within the hippocampal dentate.
ANOVA revealed significant effects of age [F(1,20) = 143.6; (p < 0.001)], genotype [F(1,20)
= 8.38; p < 0.01] and of the interaction of age x genotype [F(1,20) = 11.2; p < 0.01]. Five mo-
old APP23 mice showed significantly fewer DCX positive cells than age-matched controls
[t(10) = 3.13; p < 0.05] (Fig. 3). In contrast, aged 25 mo-old APP23 mice showed a significant
increase in DCX positive cells compared to age matched controls [t(10) = 4.23; p < 0.01]
(Fig. 3), supporting the conclusion that an amyloidogenic environment  stimulates
neurogenesis and/or survival of newborn neurons.
4.4.4. Alterations of neural stem cells contacting Aß deposits
Next we intended to study whether this increase in neurogenesis is the result of an increased
number of nestin-positive neural stem cells. Nestin is an intermediate filament protein
expressed in neural stem and progenitor cells 10,38,39. However, consistent with previous reports
of a striking age-related decrease in stem cells in the SVZ 40 and poor detection of mouse
nestin with commercially available antibodies we could not detect nestin-positive cells in
significant numbers in the dentate gyrus of aged 25 mo-old mice. Thus, a recently generated
APPPS1 mouse model was used that develops cerebral amyloidosis at a much younger age
compared to APP23 mice (Radde et al., 2005). To further improve detection of stem cells we
crossed such APPPS1 mice with mice expressing GFP under a nestin promoter 30. GFP
positive cells were located at the subgranular zone (SGZ) and often extended a small but very
dense dendritic tree into the inner molecular layer (ML) (Fig. 4A).
65
Fig. 4: Neural stem cells in the GCL interact with amyloid plaques. (A) Adult nestin-positive stem cells in the
GCL of aged 8 mo-old GFP-wt mice. Quiescent astrocyte-like stem cells (open arrows) were located along the
GCL, with their cell body in the SGZ and dendrites in the molecular layer perpendicular to the GCL. In contrast,
transient amplifying precursor cells (close arrows) in the SGZ displayed a horizontal orientation (B) In GFP-
APPPS1 mice, amyloid deposits (congo red staining in red) strongly attracted the dendrites of quiescent
astrocyte-like (open arrows) and transient amplifying cells (close arrow). Scale bar: 50µm. (C) High
magnification of the typical morphological alterations of a quiescent astrocyte-like cell attracted to Aß (red).
Note the thickened main branch of the dendrite tree (close arrow) and the thickened dendrites in close vicinity to
the plaque (open arrows). (D) Transient amplifying cells were found to react to the presence of Aß similar to
quiescent astrocyte-like cells with thickened processes (close arrows) and an aberrant dendritic tree sheathing
the amyloid plaque with dystrophic bouton-like structures (open arrow). Scale bar: 10µm. (E) Stereological
estimates of quiescent astrocyte-like stem cells revealed a significant reduction in 8 mo-old GFP-APPPS1 (n=8)
compared to age-matched GFP-wt mice control mice (n=7) (*p < 0.05). (F) No difference occurred in the
number of transient amplifying progenitor cells in GFP-APPPS1 compared to GFP-wt mice.
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These putative neuronal stem cells have been described as radial astrocytes 41 or as quiescent
astrocyte-like “Type -1” cells 42,43 and are characterized by co-expression of nestin and GFAP
but lack of S100ß or DCX expression. This phenotyping has also be confirmed in our mice
using confocal microscopy and immunofluorescent multi-labeling (results not shown).
Remarkably, in 8 mo-old GFP-APPPS1 mice Aß deposits in the ML strongly attracted
dendrites of these putative neural stem cells. This was accompanied by morphological
alterations in these cells, including thickened processes and hypertrophic dendrites aberrantly
contacting Aß plaques (Fig. 4). Estimates of total nestin-GFP positive quiescent astrocyte-like
stem cells in amyloid-depositing 8 mo-old GFP-APPPS1 mice showed a significant reduction
in number compared to GFP-wt control mice [t(13) = 4.84; p < 0.05; n=7-8/per group] (Fig.
4E).
As neural stem/progenitor cells begin to differentiate, GFAP expression is extinguished and
cells adopt a migratory-like morphology with a major axis tangential to the GCL. These cells
have been referred to as “Type-II” cells 42,43 or D cells 44 and represent a transient amplifying
population of neural progenitor cells (Fig. 4). These GFAP-negative and nestin-positive cells
were also found to extend aberrant processes to amyloid deposits (Fig. 4D), but their total
number did not differ between GFP-APPPS1 and GFP-wt mice [t(13) = 0.53, p>0.05] (Fig.
4F).
Surprisingly, unlike nestin expressing stem cells, DCX-positive immature neurons appeared
morphologically unaltered by Aß-deposits, extending dendrites close to and past amyloid
plaques without showing any attraction or thickening (results not shown).
Together, these results provide evidence that neurogenesis and the population of immature
neurons is increased in an amyloidogenic environment, while neural stem cells are decreased
and strongly affected by the presence of Aß.
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4.5. Discussion
In this study we investigated the behavior of neural stem cells and neurogenesis in the context
of cerebral amyloidosis. Results revealed no differences in neurogenesis in pre-amyloid
depositing 5 month-old APP23 mice but a significant increase in neurogenesis in aged 25 mo-
old APP23 mice compared to age matched wild type mice.
In an effort to study whether the increase in neurogenesis is already reflected at the level of
nestin-positive stem cells, we found that quiescent astrocyte-like stem cells were reduced in
numbers in Aß-depositing APPPS1 mice compared to wild type mice, while the number of
amplifying stem cells remained at a similar level. Transient amplifying cells are believed to
be the more differentiated and more proliferative progeny of quiescent astrocyte-like cells 42-
44, suggesting that chronic Aß deposition is accompanied by an increase in the ratio of
transient amplifying / quiescent astrocyte-like cells, which in turn leads to increases in DCX
positive cells and up-regulation of neurogenesis overall.
Previous results on the effect of Aß on neural progenitor proliferation in the hippocampus of
transgenic mice revealed both increases and decreases of neurogenesis 45-47. However, in these
studies, transgenic mice were investigated at an early stage of amyloid deposition and thus,
results may be related to both the over expression of APP and to accumulation of Aß 48.
Consistent with our results, investigation of the postmortem AD brain showed an increased
expression of markers of proliferation and immature neurons in the hippocampus 49.
It is surprising that neurogenesis, which is thought to be important for hippocampus-related
memory, is increased in both aged Aß-depositing mice and in AD patients. As in AD humans,
previous behavioral experiments with APP23 and other AD mouse models have shown
impairment in hippocampus-dependent memory tasks 50-53, suggesting that increased
neurogenesis is not sufficient to overcome the more global neural dysfunction induced by
amyloid deposition. Newborn neurons are known to be incorporated into functional neural
networks and this has been shown to correlate with improved learning and memory 2,6,54.
However, the elevation in newborn neuron numbers in AD patients and mouse models is
accompanied by deficits in learning and memory. Given our finding for grossly altered
progenitor cell morphology and arborization, it seems possible that neurogenesis in an
advanced amyloidogenic environment is accompanied by altered connectivity and perhaps
aberrant function 55.
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Amyloid-dependent up-regulation of neurogenesis is likely caused by a combination of
several mechanisms. It is known that amyloid deposits stimulate the local accumulation of
several growth factors that are potent regulators of neurogenesis; these include BDNF, VEGF,
FGF, and CystatinC 16-18,56. A neurogenic effect of Aß peptide on hippocampal neural stem
cells has also been reported 57. The elevation in neurogenesis may also represent an
endogenous neural replacement response to cell death rather than a direct response to
amyloidogenesis. Indeed, neurogenesis in the hippocampus is stimulated in response to a
variety of insults such as cerebral ischemia, seizure or neurotoxic lesions 58-61. In both AD
patients and APP23 mice, neuronal cell loss in the hippocampus has been reported 62,63.
In conclusion, our present finding demonstrates a disruption of neural stem cell biology in an
amyloidogenic environment with a concomitant stimulation of neurogenesis. This increase in
neurogenesis may be compensatory and reflect a remarkable endogenous potential for
neuronal replacement in an amyloidgenic environment. However, such a response still
appears insufficient to overcome the more global neurodegeneration and associated cognitive
deficits in AD and mouse models. It is also possible that neurogenesis in an amyloidogenic
environment is aberrant and dysfunctional. Thus it remains to be determined if ablating
neurogenesis in aged Aß-accumulating mice improves or harms hippocampal function which,
in turn, will be of major relevance for the development of therapeutic strategies.
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4.6. Supplementary Data
4.6.1. Neurogenesis in running mice
Although reports about the beneficial effects of exercise for AD patients are conflicting,
studies with rodents provide growing evidence that exercise improves both cognitive
performance and neurogenesis 5,64. To determine the influence of running on neurogenesis in
aged APP23 mice, 5 month-old and 25 month-old APP23 mice and littermate (N=6) were
provided with running wheels and allowed to run voluntarily for 4 weeks. To determine if
there were differences in voluntary use of the running wheel between APP23 and wild type
mice, the night before sacrificing, running was monitored in a darkened room for two hours.
Every five minutes (24 determinations over 2 hours), wheel-use was scored as + or -. We
found that aged mice utilize the running wheel approximately one half as much as 5 month-
old adult mice, but there were no significant differences between age-matched APP23 and
wild type mice (96%, 100%, 40% and 52% for young APP23, young controls, old APP23 and
old controls respectively).
Fig. 5: Exercise does not increase neurogenesis in aged APP23 mice. After four weeks with access to a running
wheel the numbers of BrdU positive (A), BrdU/NeuN double positive (B) and DCX positive (C) cells in the GCL
are at the same levels in 25 months old APP23 and age matching type control mice.
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Stereological evaluation of BrdU incorporation in 5 month-old animals showed that
proliferation increased equally in both genotypes (data not shown).  In aged animals, running
also stimulated BrdU incorporation in wild type animals but had no significant effect in
APP23 mice (Fig. 5A; p > 0.05). Similarly, comparing the numbers of BrdU/NeuN, and DCX
positive cells in aged APP23 and control mice after 4 weeks of running revealed that running
normalized the differences in net neurogenesis between APP23 and wild type mice (Fig.5 B-
C). No differences in plaque load were observed between running and normally housed
APP23 mice (14.0% ± 1,9% by tissue area in standard housed mice vs. 16.5% ± 1.5% in
running mice).  Together, the data suggests that plaque deposition is accompanied by an
increased neurogenesis but that running has no further stimulatory effect on neurogenesis in
these animals.
4.6.2. Accumulation of neurosphere building stem cells in the hippocampus of 24 months old
APP23 mice
Because of the lack of good markers to label neural stem cells the methods to determine the
number of neural stem cells in the hippocampus are limited. Incorporation of BrdU can only
serve as an estimate of the numbers as the result is biased by availability of BrdU in the
system of the animal or division rates of dividing cells. Isolated neural stem cells do not
aggregate but grow clonally into floating spheres, called neurospheres 65. In this in vitro essay,
we estimated the number of stem cells by counting the neurospheres grown from the total
stem cell population we extracted from the hippocampus.
Whole hippocampal lobes were dissected from 4 month and 24 month old APP23 and B6
control mice (N=3). Tissues were enzymatically digested with a mixture of papain, neutral
protease and DNAse and then fractionated on a Percoll step gradient. Cells floating on a
65–35% interface were collected and plated into un-coated dishes in defined medium
containing Neurobasal, B-27 supplement (Gibco, Carlsbad, California) and 20 ng/ml FGF-2
(Peprotech, Hill, New Jersey) and 20 ng/ml EGF (Sigma). After three days the number of
spheres was counted at low magnification.
After three days in culture neural stem cells had grown into easily identifiable spheres (Fig. 6
A). To confirm the neuronal nature of the precursor cells, we induced differentiation and
stained for neuronal and astrocytic markers (Fig. 6 B). The number of sphere growing stem
cells confirmed the influence of Aß on neurogenesis that we portrayed in the results of the
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experiments with BrdU and DCX; the number of spheres taken from young APP23 animals
was reduced compared to controls, but we found a large excess of neurospheres from aged
APP23 hippocampus relative to aged control mice (Fig. 6 C). These findings indicate that the
effects of Aß on neurogenesis, are a result of the influence of Aß on the size of the stem cell
population.
Fig. 6: Neurosphere assay from hippocampal progenitor cells. (A) Neural stem cells grow to Neurospheres in
culture. (B) Cells outgrowing from neuropheres can differentiate into neuronal (ß-tubulin III, green) or
Astrocytes (GFAP, red). (C) The number of neural stem cells does not wane in aged WT animals. In APP23
there is a reduction in predepositing mice, but increased numbers in aged mice with a large plaque load.
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5.1. Abstract
The significance of the peripheral immune system in Alzheimer's disease pathogenesis
remains controversial. To study the CNS invasion of hematopoietic cells in the course of
cerebral amyloidosis, we used a green fluorescence protein (GFP)-bone marrow chimeric
amyloid precursor protein transgenic mouse model (APP23 mice). No difference in the
number of GFP-positive invading cells was observed between young APP23 mice and non-
transgenic control mice. In contrast, in aged, amyloid-depositing APP23 mice a significant
increase in the number of ameboid-like GFP-positive cells was found compared to age-
matched non-transgenic control mice. Interestingly, independent of the time after
transplantation (3-10 months) only a subpopulation of amyloid deposits were surrounded by
invading cells. This suggests that not all amyloid plaques are a target for invading cells or,
alternatively, all amyloid plaques attract invading cells but only for a limited time, possibly at
an early stage of plaque evolution. Immunological and ultrastructural phenotyping revealed
that macrophages and T-cells accounted for a significant portion of these ameboid-like
invading cells. Macrophages did not show evidence of amyloid phagocytosis at the electron
microscopic level and no obvious signs for T-cell mediated inflammation or
neurodegeneration was observed. The observation that hematopoietic cells invade the brain in
response to cerebral amyloidosis may hold an unrecognized therapeutic potential.
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5.2. Introduction
The pathological hallmarks of Alzheimer’s disease (AD) include the presence of ß-amyloid
plaques, neurofibrillary tangles and neuron loss 1. These pathological changes are invariably
accompanied by an associated inflammatory reaction involving microglia and astrocytes 2.
Accumulating data suggest, that microglia, as the brain resident macrophages, play a key role
in mediating this inflammatory reaction 2-4. Although excessive migration of peripheral cells
into the CNS of AD patients has not been described, in vitro studies have demonstrated the
ability of Aß to stimulate production of a number of cytokines and chemokines from human
microglia 5-7. Thus, it is likely that chemokines together with other inflammatory mediators
are able to recruit peripheral immune cells into the AD brain, which, in turn, may contribute
to AD pathogenesis.
The lack of a single defining marker to distinguish invading cells from resident and activated
microglia makes the study of these potent immune regulatory cells difficult. Recently, the
need for about ten different markers to unequivocally distinguish peripheral macrophages
from resident microglia has been exemplified 8. In response to these technical difficulties,
bone marrow transplantation techniques have become an important tool to study the invasion
of peripheral cells into the healthy or diseased brain 9,10. Thus, to study the invasion of
peripheral immune cells in response to cerebral amyloidosis, we performed bone marrow
transplantation on different age groups of APP23 transgenic mice. APP23 mice develop
amyloid plaques as well as cerebral amyloid angiopathy (CAA) with aging and show an
inflammatory reaction to amyloid that is very similar to that seen in AD brain 11-13. Our results
in transgenic mice suggest an involvement of the peripheral immune system in cerebral
amyloidogenesis.
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5.3. Materials and Methods
5.3.1. Mice
Male APP23 transgenic mice and non-transgenic littermate controls were used 11. APP23
transgenic mice have been backcrossed to C57BL/6J mice for more than ten generations.
Hematopoietic donor cells were from C57BL/6J-TgN(ACTbEGFP)1Osb mice (Jackson
Laboratories, Bar Harbor, MN 14).
5.3.2. Transplantation
Host mice received two total body doses of cobalt radiation (500 cGray) within a three-hour
interval to minimize gastrointestinal toxicity, followed by a single tail vein injection of
approximately 5 million EGFP-positive donor cells in an injection volume of 200 µl.
Donor cells were prepared from timed pregnant embryonic day 17 old C57BL/6J-
TgN(ACTbEGFP)1Osb mice. Embryos were removed from the uterus and screened for
transgene expression using a fluorescent light. From the fetal livers of the EGFP-positive
embryos a single cell suspension was prepared by passing the suspension through a
descending line of smaller bore pipette-tips using semi-sterile conditions. Cells were washed
with RPMI containing 5% FCS (GIBCO), and the density was adjusted to 25x103 cells/µl in
HBSS (GIBCO).
Transplanted mice were kept under sterile conditions for three weeks following the procedure
before they were placed back in the regular SPF animal facilities. All experimental procedures
were in accordance with the Swiss veterinary office regulation and performed under the
approved protocol number 1864.
5.3.3. Tissue preparation and immunohistochemistry
Mice were overdosed with pentobarbital and transcardially perfused with ice cold PBS.
Brains were removed and postfixed overnight in fresh 4% paraformaldehyde in PBS. After
fixation the brains were placed in 30% sucrose in PBS for 2 days. Brains were subsequently
frozen in 2-methylbutane and stored at –70°C until further use.
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Coronal sections (25 µm) were cut on a freezing-sliding microtome into cryoprotectant
solution (30% ethylenglycol, 20% glycerol, 50mM sodiumphosphate buffer, pH7.4). Sections
were rinsed several times in PBS and incubated in 0.08% H2O2 in PBS, followed by an
incubation in PBS containing 0.3% Triton X-100 and 5% serum. Primary antibody was
diluted in PBS with 2% serum and 0.3% Triton X-100 all in PBS and incubated at 4°C
overnight. Sections were then incubated with biotinylated secondary IgG followed by the
avidin–biotin–peroxidase complex solution (all from Vector Laboratories; Burlingame, CA).
Sections were incubated with Vector SG-blue (Vector Laboratories) in PBS for 2 min, rinsed,
dehydrated, cleared, and coverslipped. The following antibodies were used: rabbit anti-GFP
(Chemicon; Temecula, CA); rabbit anti-Aß (NT12; Gift of P. Paganetti, Basel, Switzerland;
Sturchler-Pierrat et al., 1997); rat anti-F4/80 (BMA, Augst, Switzerland; Austyn and Gordon,
1981), rabbit anti-Iba-1 (gift of Dr. Y. Imai, Japan; Ito et al., 1998), hamster anti-mouse CD3
(Pharmingen; San Diego, CA), rat anti-B220 (Pharmingen), rat anti-mouse CD45
(Pharmingen), hamster anti-mouse CD31 (Pierce Biotechnology, Rockford, IL), mouse anti-
NeuN (Chemicon); guinea pig anti-GFAP (Advanced Immunochemical Inc., Long Beach,
CA); and rabbit anti-GFAP (Dako, Glostrup, Denmark). Amyloid plaques were visualized
either by NT12 antibody or histologically by Congo red staining according to standard
procedures.
For single and multiple immunofluoresent labeling a similar protocol was used. However,
after incubation with the primary antibody, the sections were incubated for 3 hrs with the
appropriate fluorophore-coupled secondary antibody. As secondary antibodies goat IgG
coupled to AlexaFluor® 568, AlexaFluor® 633 (Molecular Probes; Eugene, OR) and Cy5
(Jackson Immunoresearch; West Grove, PA) were used. Sections were rinsed in PBS and
coverslipped in polyvinylalcolhol mounting medium with DABCO (1,4-diazabicyclo {2,2,2}
octane; Fluka, Buchs, Switzerland). Sections were analyzed with a Confocal Laser Scanning
Microscope (LSM 510 Meta, Axiovert 100M; Zeiss, Jena, Germany).
5.3.4. Stereological assessment of GFP-positive cells
The total number of GFP-positive cells in the neocortex was estimated using the optical
fractionator technique 15. Neocortical borders were defined based on a mouse brain atlas 16.
Quantifications were performed on a systematic random series of every 12th GFP-peroxidase
stained coronal section throughout the entire neocortex. The sum of counted cells was
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multiplied by the reciprocal of the fraction of the brain region sampled, resulting in the total
number of GFP-positive cells/neocortex. In a second step, the GFP-positive cells in the cortex
were recounted and subdivided in five morphological subgroups of ameboid, round, rod,
elongated and stellate cell 9.
5.3.5. Quantification of plaque load and vascular amyloid
A systematic random series of every 12th Aß-immunostained (NT12 antibody) section
throughout the entire neocortex was selected per animal. Plaque load was estimated by
calculating the area fraction occupied by parenchymal amyloid in two-dimensional counting
frames on a single focal plane (20X objective, 0.6NA) 17. Stereological analysis was
performed with the aid of Stereo Investigator software (Microbrightfield; Williston, VT) and
a motorized x–y–z stage coupled to a video-microscopy system (Systems Planning and
Analysis Inc.; Alexandria, VA). On the same set of Aß-immunostained sections cerebral
amyloid angiopathy (CAA) was quantified by estimation of CAA frequency, severity and
CAA score according to a previously published method 12.
5.3.6. Association of GFP-positive cells with amyloid plaques and vascular amyloid
A systematic random series of every 12th section was stained for Congo red and
immunostained for GFP. Plaques with one or more GFP-positive cells touching the
congophilic center or their direct perimeter (halo) were counted.
5.3.7. Electron microscopy
Mice were deeply anaesthetized and transcardially perfused with a fixative containing 4 %
paraformaldehyde and 0.1 % glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.4). Brains
were removed and postfixed for 24 h in 4 % paraformaldehyde in 0.1 M PB. Frontal sections
of the hippocampus (50 µm) were cut with a vibratome and washed in 0.1 M PB. After a
blocking step (5 % BSA in 0.1 M PB), free-floating serial sections of each brain were
incubated with an anti-GFP antibody (Clontech; Palo Alto, CA) at 4° C for 24 h. The sections
were then incubated with a biotinylated secondary antibody (anti-rabbit IgG; Vector Labs) at
room temperature for 90 min. After rinsing in 0.1 M PB, sections were exposed to an avidin-
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biotin-peroxidase complex (ABC-Elite, Vector) for 2 h at room temperature. Following
several washes, the sections were immersed in a 3,3’ diaminobenzidine solution and washed
again several times. They were then contrasted with osmium (0.5 % OsO4 in 0.1 M PB) for
20 min, dehydrated (70 % ethanol containing 1 % uranyl acetate) and embedded between
liquid-release-coated slides and coverslips. Selected sections were re-embedded in Durcupan
blocks (Fluka, Steinheim, Germany) for ultrathin sectioning. Sections collected on single-slot
Formvar-coated copper grids were examined in a Zeiss electron microscope.
5.3.8. Quantitative assessment of GFP-positive macrophages and T cells
To estimate the percentage of macrophages in the population of GFP-positive ameboid cells,
4 sections from the systematically sampled set of sections were double-stained for Iba-1 and
F4/80 and analyzed by confocal microscopy. The percentage of macrophages was estimated
by analyzing 40 GFP-positive ameboid cells per animal that were labeled with at least one of
the two macrophage markers. To identify T cells among the GFP-positive ameboid cells
another set of 4 sections per animal was stained using a T cell specific antibody (CD3). The
percentage of T cells was estimated by counting 30 GFP-positive ameboid cells per animal
and calculating the proportion of CD3-positive cells.
For ultrastructural identification and phenotyping, 34 randomly selected plaque associated
GFP-immunopositive cells in two animals were analyzed and phenotyped based on size,
shape, lymphocyte-typical nuclear fold, and/or the presence macrophage-typical phagosomes.
5.3.9. Statistical analysis
Results were analyzed using Student’s t-test with the help of StatView 5.0.1. Where
appropriate Bonferroni correction for multiple data sets was used. Data are presented as the
mean + SD. Statistical significance was accepted as p<0.05.
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5.4. Results
To examine the invasion of bone marrow-derived cells in response to cerebral amyloidosis,
we reconstituted irradiated APP23 mice with syngenic hematopoietic cells expressing GFP.
Experimental groups of non-transgenic and transgenic male mice were transplanted at
different stages of amyloidosis with various times of survival thereafter (Fig. 1). Group 1 was
transplanted at 6 months, an age prior to the deposition of cerebral amyloid, and was
sacrificed 10 months later. In contrast, group 2 and 3 received their hematopoietic graft at an
age with existing amyloidosis (15 and 20 months) and were analyzed 3 and 5 months later,
respectively. As control, group 4 was transplanted and analyzed before mice developed
amyloid deposits (Fig. 1).
Figure 1:  Experimental groups studied. APP23 mice and littermate controls at various ages were lethally
irradiated and transplanted with GFP-positive bone marrow (Bm). After different times following this procedure
the invasion of peripheral bone marrow cells was analyzed in the neocortex. The following numbers of mice
were used per group: Group 1: 3 controls; 8 APP23. Group 2: 4 controls; 4 APP23. Group 3: 6 controls; 3
APP23. Group 4: 5 controls; 5 APP23.
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5.4.1. Increased invasion of hematopoietic cells in amyloid-bearing APP23 mice
To determine the number of bone marrow-derived cells in the brain of APP23 mice, GFP-
positive cells were visualized by immunohistochemistry with an antibody against GFP (Fig.
2). Analysis focused mainly on the neocortex because this region exhibited the most robust
amyloid pathology.
In non-transgenic control mice, the majority of GFP-positive cells were located in
perivascular spaces, in the meninges and in the ependymal lining of the ventricles and choroid
plexus. Only few cells were seen in the parenchyma, and the vast majority of these cells were
vessel associated (Fig. 2A). This observation is consistent with previous reports 9,18 and was
true for all non-transgenic animals of the four experimental groups, i.e. independent of the age
at which the mice received the bone marrow transplant and independent of the age at which
the mice were analyzed (Fig. 1).
In contrast, in amyloid-depositing APP23 mice (group 1-3, Fig. 1) a significant portion of
GFP-positive cells was found in the parenchyma in particular in neocortical areas with a high
amyloid load (Fig. 2A). The total number of GFP-positive cells was strikingly increased
compared to non-transgenic control mice. Stereological analysis revealed a 52% increase for
group 1 (Fig. 2C) and 76% and 85% increases for group 2 and 3, respectively.
Morphological analysis of GFP-positive cells in non-transgenic and transgenic mice revealed
five subgroups of GFP-positive cells consistent with morphological criteria previously
suggested 9: Ameboid-like cells (Fig. 2B) contained extensive cytoplasm, had often small
projections and were predominately found in the brain parenchyma. They were rarely seen in
the neocortex of non-transgenic control mice, but were abundant in amyloid-bearing APP23
mice. Quantitative analysis demonstrated a 7-fold increase of these cells in amyloid-bearing
mice compared to non-transgenic controls (Fig. 2C). Round cells (Fig. 2B) were smaller,
typically only 5-10µm in diameter, found mainly in vessels and did not enter the parenchyma.
No difference was found between non-transgenic and amyloid-bearing APP23 mice (Fig. 2C).
Rod-like cells (Fig. 2B) showed a distribution similar to the round cells. Again, no difference
was found between non-transgenic and APP23 mice (Fig. 2C). Elongated cells (Fig. 2B)
extended up to 100 µm along the vasculature and were always intimately associated with
vessels of all calibers. They were the most abundant cells in non-transgenic control and in
amyloid-bearing APP23 mice. However, no difference was noted between the groups (Fig.
2C). Stellate cells (Fig. 2B) were only found in the subventricular regions that lack a blood
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brain barrier (e.g. arcuate nucleus, median eminence). No difference was noted between non-
transgenic control and amyloid-bearing APP23 mice (Fig. 2C).
In APP23 transgenic mice sacrificed prior to the onset of cerebral amyloidosis (group 4), no
significant increase of the total or any subgroup of GFP-positive cells was found (Fig. 2C).
This observation suggests that the mere overexpression of APP and the presence of soluble
human Aß did not affect the migration pattern of peripheral cells.
Figure 2: Increased invasion of peripheral cells
into the neocortex of amyloid-depositing APP23
mice. (A ) Neocortex of a 16 mo-old control
mouse and 16 mo-old APP23 mouse showing the
distribution of GFP-positive cells (here
immunostained with an antibody to GFP).
Congophilic plaques are shown in red.
Calibration bar is 100µm. Insert shows a GFP-
positive cell closely associated with an amyloid
plaque. (B ) GFP-positive cells were
morphologically classified in 5 distinct
subgroups. Scale bars are 20 µm. ( C )
Quantification of total GFP-positive cells
revealed a 52% increase (*p<0.05) in neocortex
of APP23 mice compared to control mice
(shown are results for Group 1, see Fig. 1).
When GFP cells were sub-grouped, only
ameboid cells were significantly increased (7-
fold, p=0.002). Similar analysis for Group 2 and
3 also revealed significant increases in ameboid
cells (p=0.006 and p=0.01, respectively) but not
any other cell subtype. No differences in total
number or any subgroup of GFP-positive cells
were found in young, pre-depositing APP23
mice (Group 4, see Fig. 1).
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5.4.2. Association of ameboid cells with amyloid
To investigate the amyloid dependence of ameboid cell invasion, correlative analysis was
done between plaque load and number of ameboid cells in neocortex of mice in group 1.
Although results indicated a positive relationship, analysis did not reach statistical
significance (Fig. 3A). A similar analysis for vascular amyloid (CAA), the extend of which is
not dependent of plaque load 12, also failed to reveal a significant correlation, although a
positive trend was again observed (Fig. 3B). The results obtained for group 2 and 3 showed
the same trend (data not shown).
Histological analysis of the association of ameboid cells with amyloid plaques revealed that
only a subpopulation of amyloid plaques was decorated with ameboid GFP-cells (Fig. 3C)
while neighboring amyloid lacked completely any association with ameboid GFP-positive
cells. The mere size of the plaque appeared not to be critical for an association with GFP-
positive ameboid-like cells. To estimate the percentage of amyloid plaques decorated with
ameboid GFP-positive cells, the number of congophilic plaques with associated GFP-positive
cells was quantified. Results for group 1 revealed that 20±4% plaques were associated with
invading ameboid cells. No other morphological difference was noted between plaques with
or without such invading cells (Fig. 3C).
Figure 3: Ameboid-like cells are associated with a subpopulation of amyloid deposits. (A) Neocortical plaque
load of the APP23 mice of group 1 was stereologically estimated and correlated with the number of invading
ameboid-like GFP-positive cells. Results indicate a positive relationship between plaque load and number of
invading cells, although the correlation did not reach statistical significance. (B) Similarly, correlative analysis
between CAA frequency and ameboid cell count revealed a positive trend. (C) Photomicrograph exemplifying
the heterogeneous distribution of invading peripheral cell in relation to amyloid plaques. Some plaques were
surrounded by a high number of invading cells, while neighboring plaques completely lacked invading
peripheral cells. Amyloid is stained with Congo red, GFP-immunopositive cells are represented in black.
Calibration bar is 75µm.
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To follow the hypothesis that newly developing amyloid deposits are able to attract peripheral
cells in a time dependent fashion, the same analysis was done for groups 2 and 3, which
varied in the time they held the transplant (3 and 5 months, respectively, as compared to 10
months in group 1). Results revealed that 27±2% and 18±4% of amyloid plaques in group 2
and 3, respectively, were surrounded by invading cells. This observation suggests that the
association of peripheral cells with amyloid plaques is not increasing with time or with
amyloid load.
5.4.3. Identification of cell type and function
Phenotyping of ameboid-shaped GFP-positive cells was done using confocal and electron
microscopy (Fig. 4). To identify macrophages at the confocal level, a combination of two
markers (F4/80, Iba-1) was used to ensure the detection of different activation states of these
cells 8. GFP-positive cells were counted as macrophages if they expressed at least one of the
two markers (Fig. 4A-E). Quantitative analysis (5 randomly selected mice of group 1)
demonstrated that 7% of GFP-positive ameboid cells were macrophages. A similar analysis
using an antibody against the pan-T cell marker CD3 was done to identify T-cells among the
GFP-positive ameboid cells (Fig. 4F-I). Results revealed an unexpectedly high percentage of
27% T-cells amongst the ameboid GFP-positive cell population in neocortex. Both,
macrophages and T-cells, were randomly distributed throughout the neocortex and both
revealed an association with a subpopulation of amyloid plaques. These amyloid plaques were
always also surrounded by resident microglia, i.e. GFP negative and Iba1-positive cells. No
B220-positive B cells could be detected (data not shown).
All GFP-positive cells found in the neocortex, independent of their morphological
appearance, were positive for CD45 confirming their hematopoietic origin (data not shown).
Consistent with this observation, confocal analysis using markers for endothelial cells
(CD31), neurons (NeuN), and astrocytes (GFAP) did not reveal any GFP-positive cells that
expressed one of these markers. These observations suggest that invading cells kept their
hematopoietic identity and did not differentiate into another brain resident cell type. To
confirm the identity of macrophages and T-cells at the ultrastructural level, electron
microscopic analysis was done in two additional APP23 mice with a bone marrow transplant
analogous to group 3.
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Figure 4: A subpopulation of the ameboid-like cells are macrophages and T-cells. (A-I) The fraction of
macrophages and T-cells in the ameboid cell population was determined by investigating ameboid-shaped GFP-
positive cells for co-labeling with a combination of different antibodies using confocal microscopy. To identify
macrophages, ameboid-like cells that are positive for GFP and positive for either Iba-1 and/or F4/80 were
identified. (A) GFP; (B) amyloid-staining using Thioflavin-S; (C) Iba-1; (D) F4/80; (E) merged images. Note
the ameboid-like GFP-positive macrophage which is Iba-1-positive but apparently negative for F4/80 (arrow).
To identify T-cells, ameboid-like GFP-positive cells that are positive for CD3 were identified. (F) GFP; (G)
CD3; (H) amyloid staining using NT12; (I) merged images. Another GFP-positive and CD3-positive ameboid-
like cell is shown in the insets (F-I). (J,K) Electron microscopy was used to identify GFP-positive cells that can
be appreciated by the electron-dense immunoprecipitate in the cytoplasm. Shown in (J) is a macrophage that
contains a phagosome (arrow) in its cytoplasm. The nucleus is indicated by a circle. A T-cell-like cell is shown
in (K) with its typical nuclear fold (arrowhead). The insets (J,K) are lower magnifications (small arrows
indicate the analysed cell; asterisks indicate the amyloid plaque). Scale bars: 10 µm (E, I); 2 µm (J, K); and 20
µ m  ( i n s e t s  i n  J ,  K ) .
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Amyloid-associated GFP-positive cells were randomly analyzed and the percentage of
macrophages and T-cells determined. Cells that were 9-12 µm in diameter and contained a
round nucleus and phagosomes were counted as macrophages (Fig. 4J). Cells that were 6-10
µm in diameter with a characteristic nuclear fold were identified as lymphocytes (Fig. 4K).
Results revealed that 23% were macrophages and 31% lymphocytes. The higher percentage of
macrophages at the ultrastructural level compared to the confocal analysis is at least partly the
result of the different sampling methods. A random selection of ameboid cells in the
neocortex was analyzed at the confocal level, while for electron microscopy preferentially
plaque-associated cells were analyzed (but see also discussion). The high percentage of T-
cells at the ultrastructural level confirmed the observation at the confocal level.
5.4.4. Lack of amyloid phagocytosis by peripheral macrophages
Our previous work suggested lack of amyloid phagocytosis in aged APP23 transgenic mice
13,19. To examine the possibility that peripheral macrophages rather than microglia are capable
of phagocytosis we examined the 8 previously identified GFP-labeled ameboid cells with
macrophage-like ultrastructural features (Fig. 4J). However, analysis of GFP-positive
macrophages did not reveal any indication of amyloid phagocytosis of these cells although
they were in close vicinity of amyloid deposits (Fig. 4J). However, many macrophages with
phagosomes containing unidentified, nonfibrillar material were observed.
5.4.5. No signs of T-cell mediated inflammation
T-cells were distributed throughout the parenchyma with some cells loosely associated with a
subpopulation of amyloid plaques. However, there was no indication of a productive
inflammation or even encephalitis, with associated tissue damage, edema, or vascular changes
(data not shown). While the number of peripheral cells was clearly increased in the brain of
APP23 mice, the distribution of cells was highly variable and there were no significant
clusters of T-cells either around vessels (vasculitis) or around plaques or other structures
indicative of a destructive process.
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5.5. Discussion
Neuroinflammatory changes in human brain and transgenic mouse models are an integral part
of the AD pathogenesis. While the significance of this neuroinflammation is a matter of lively
debate (reviewed in 2, the contribution of the peripheral immune system to neuroinflammation
and AD pathogenesis has not received similar attention. However, in the light of recent
therapeutic Aß vaccination trials, the role of the peripheral immune system has been
exemplified by the unexpected immunotherapy-induced occurrence of meningoencephalitis 20-
22.
Our present results demonstrate that bone marrow-derived cells access the amyloid-laden
brain in significantly higher numbers than compared to controls. The invading cells remain of
hematopoietic phenotype and are heterogeneously scattered throughout the brain. About 20%
of congophilic plaques were surrounded by GFP-positive ameboid-like peripheral cells, and
this percentage did not change with increasing time after bone marrow transplantation. Even
in mice that received the transplant before the onset of cerebral amyloidosis, the percentage of
plaques that were surrounded by such peripheral ameboid-like cells remained approximately
20%. This observation indicates that only a subpopulation of amyloid plaques is a target for
invading cells. Alternatively, all amyloid plaques might attract invading cells but only for a
limited time, possibly at an early stage of plaque evolution.
Dying cells are the classical activator and target of phagocytic cells such as bone marrow
derived invading macrophages 10,23. It is therefore interesting to speculate, that plaques with
GFP-positive cells represent a toxic stage, which attract macrophages to clear the cellular
debris. However, the significance of such phagocytosis by peripheral macrophages and its
relation to the proliferation of amyloid associated resident microglia is not clear 17,24. Such an
interpretation would however imply that only a subpopulation of plaques are toxic to their
environment. Alternatively, plaques might be toxic only at an early stage of development and
the presence of peripheral cells leads to a detoxification.
The finding that only a small percentage of the invading ameboid-like cells could be
identified at the light microscopic level as macrophage is at first glance surprising. However,
it is known that many of the macrophage markers, including Iba-1 and F4/80, are
differentially regulated in the activation process and are downregulated when the cells enter
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the CNS 25. Thus, it is possible that the number of invading macrophages is underestimated by
number supporting the observations at the ultrastructral level.
Peripheral macrophages are predominantly MHCII- and Fc gamma receptor (FcgR)-positive
and represent the innate immune response. They are thought to be involved in amyloid
phagocytosis 26. However, although our results point to a tight association of such
macrophages with amyloid bundles at light microscopic levels, electron microscopy did not
reveal any signs of amyloid phagocytosis, i.e. complete engulfment of amyloid-fibrils by the
macrophage cytoplasm. We have previously shown, that the same observation is true for
activated resident microglia, which also lack the capacity for amyloid phagocytosis in APP23
transgenic mice 13,19.
The present finding of significant invasion of T-cells in response to cerebral amyloidosis was
unexpected in light of previous findings. In an earlier study we did not detect any
lymphocytes in APP23 transgenic mouse brain 27. In the present study we have irradiated the
mice, a process that is known to temporarily activate and open the blood brain barrier and
increase the level of inflammation by activation of glial cells 28. Thus, it is possible that this
irradiation-induced increase in the level of chemoattractants and cytokines contributed to the
invasion of T-cells. This would be consistent with the view that the lack of lymphocytes in
most animal models of AD is due to the generally lower level of inflammation in the mice
compared to the AD brain.
However, irradiation itself cannot be the sole cause of the increased lymphocytic infiltration
in the present study since such an increased invasion was not found in control mice.
Moreover, at the time points examined in this study there was no detectable blood brain
barrier leakage (assessed by anti-IgG immunostaining). However, it is possible that the
presence of vessel-associated amyloid prevents the “healing” of the radiation-induced vessel
damage, allowing for an increased infiltration of leucocytes in the transgenic mice. This
hypothesis could be addressed by irradiating the mice and protecting the brain by lead hats 29.
The discrepancy between the failure to see lymphocytes in our previous study and the
invasion of T-cells in the present study, may also be that in the present study peripheral cells
can easily be detected by their GFP-expression, thereby increasing sensitivity and specificity
of detection.
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In AD brain the presence of T-cells is well documented, but their role in the disease process is
not clear 30,31. In addition, most AD patients have peripheral T-cells which are self reactive
against Aß. This is further evidence for the involvement of the peripheral immune system, in
particular the lymphocytic compartment in the pathogenesis of AD 32. However, when
compared to the overt inflammatory response associated with an acute injury of the brain or to
multiple sclerosis, the recruitment of peripheral cells in AD remains atypical. For example,
there is no indication for a productive inflammation or even an encephalitis with associated
tissue damage, edema, or vascular changes in AD 33. Similarly, while the number of
peripheral cells was clearly increased in APP23 mice, the distribution of cells was highly
variable and there were rarely clusters of T-cells observed, neither around vessels (vasculitis)
nor around plaques or any other structures, which would be indicative of a destructive
process.
It is possible that such T-cells have a function in protecting the injured CNS 34. Recent studies
suggest indeed a regulatory interaction between T cells and microglia, where T-cells limit the
destructive potential of the inflammatory reaction 35,36. Thus, the role of T-cells in AD brain
remains speculative; T-cells are present but do not show any association with tissue damage.
Further studies into the role of T-cells in AD pathogenesis are needed and will allow to
develop new and better immunization strategies, without the observed T cell-mediated
menigoencephalitis as an unwanted side effect 20-22. To this end, the herein described bone
marrow reconstituted APP transgenic mouse model may serve as a model to study such
immunotherapeutic strategies.
While the number of invading bone marrow-derived ameboid cells increased in response to
cerebral amyloidosis, the elongated vasculature-associated cells did not increase in number
and appeared not to be activated. These vasculature-associated invading cells most likely
represent perivascular macrophages. The observation, that the population of perivascular
macrophages remained unchanged was unexpected. It is thought that these cells participate in
the control and regulation of homeostasis of the interstitial space 37, which is part of the
perivascular clearance pathway of Aß 38. In atherosclerosis and stenosis the number of new
endothelial cells increases and helps to repair and restore endothelial function 39. Therefore,
we also evaluated the possibility, that these vessel associated-cells were endothelial cells.
However, based on the lack of CD31 expression and the presence of CD45, no trans-
differentiation to the endothelial cell type was noted.
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In conclusion, this study demonstrates that the peripheral immune system is associated and
likely has a role in AD pathogenesis. We show that an increased number of leucocytes enters
the brain during amyloidosis, although this does not lead to an obvious functional and
progressive immune response in the CNS. Therefore, it remains to be evaluated whether these
cells are causal, contributory or sequels of the disease process. However, the fact that they
invade and associate with the amyloid plaques together with their easy accessibility and
genetic manipulation, makes them interesting as a therapeutic vehicle for targeted intervention
10,40 which recently has been successfully demonstrated for a lysosomal storage disease 10,40.
Harnessed with an amyloid degrading enzyme or an immune modulator, autologous bone
marrow-derived cells may offer a potent, targeted therapeutic strategy of clearing amyloid
deposition and/or reducing amyloid-associated neurodegeneration.
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6. Conclusions
The goal of these studies was to investigate the role of hippocampal neurogenesis in the aged
and AD brain, to identify the disturbances of neural stem cell biology in the amyloidogenic
environment and to assess strategies to ameliorate impaired neurogenesis.
We found a decreased neurogenesis in aged animals, with a major decrease from juvenile to
adult mice, but only little decline in aged compared to adults. The finding that calorie
restriction, a treatment that is consistently beneficent to age related deficits, does not increase
the rate of neurogenesis confirmed that at least at the adult stage, there is only a minor age
related defect of neurogenesis.
The level of neurogenesis has been shown to correlate with the performance in hippocampus
dependent memory tasks 1-4. In aged animals however, the relationship of memory and
neurogenesis remains controversial 5,6, indicating that neurogenesis might only be relevant for
memory if it is above a certain threshold and/or that neurogenesis becomes irrelevant for
memory with progressive age. We found an increased neurogenesis in aged APP23 mice,
which are known to be impaired in hippocampus dependent memory 7-9, providing further
evidence that neurogenesis in aged mice is irrelevant to memory.
An experiment investigating neurogenesis in APP23 mice with access to a running wheel
strengthened this hypothesis even more; voluntary running is known to increase neurogenesis
and has also been shown to have a beneficial effect on memory 1,10 and more importantly on
cognition of senile and AD patients 11-13 and AD mouse models 14,15. Here, we found no
increase beyond the pre-existing elevation in neurogenesis in exercising animals carrying
heavy plaque loads. Again, this suggests that cognitive performance in animal models of AD
does not dependent on neurogenesis. Recent studies with AD mouse models suggest, that Aß
related memory deficits are caused by small assemblies of Aß that occur as a pre-stage of Aß
plaques and affect the synapses 16-18. Removal of these assemblies resulted in improved
memory, without reducing plaque load 17,19, and we speculate that running induced memory
enhancement in AD mouse models depends on a similar mechanism. We surmise that
hippocampus dependent memory depends on neurogenesis in juvenile and early adult mice,
but with progressive age relies more on synaptic plasticity of the existing cellular architecture.
Our observations in Aß depositing mice with genetically marked stem cells demonstrate, that
stem cells residing in the GCL are highly disturbed and reduced in numbers. However, the
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numbers of more differentiated, and highly proliferative neural precursor cells remained
constant and are most likely responsible for the increased neurogenesis found in the AD
mouse model. This result was confirmed by the finding that an excess number of
neurospheres was produced by the extracted population of neural precursor cells from aged
APP23 hippocampi. The functional reason of this increased neural stem cell proliferation
could not be investigated, but it is possible that the up-regulation of neurogenesis reflects a
compensational mechanism for AD related defects in the hippocampal network.
Potentially stem cells could be used as therapeutic agents in neurodegenerative diseases. Most
elegantly, the endogenous stem cell population could be stimulated for the regeneration of the
damaged tissue. Here, we found that although running can stimulate neurogenesis in adult and
aged laboratory mice, it does not increase neurogenesis in the AD mouse model. Moreover,
new neurons in aged animals are produced at such a low rate, that it seems unlikely, that
neurogenesis can participate in the replacement of neurons in the degenerating brain. Our
studies with hematopoietic stem cells invading the brain of APP23 mice revealed that
peripheral cells do not replace damaged neurons. However, the invasion of peripheral cells
into the brain was much greater than expected and the attraction of certain cells to Aß deposits
makes them a potential carrier to deliver a neuroprotective drug or an Aß dissolving agent to
the site of the Aß plaque.
In summary, we conclude that hippocampal neurogenesis has only limited importance for
memory in aged mice. Consequently, we surmise that the various alterations of neural stem
cell biology induced by Aß do not contribute to AD related memory impairments. In addition,
we found that the endogenous hippocampal stem cell population could not be stimulated to a
degree that would enable the repair of serious brain damage or neuronal degeneration.
However, it is astonishing that neurogenesis persists until senescence. The role of adult
neurogenesis remains elusive, but the Aß induced disturbances described here raise new
questions about its function (or dysfunction in the AD brain) and provide a background for
future investigations.
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Abbrevations
Aß ß-amyloid
ACE angiotensin converting enzyme
AD Alzheimer’s disease
AL ad libitum
ANOVA analysis of variance
APH-2 anterior pharynx-defective phenotype
APOE apolipo protein E
APP amyloid precursor protein
BDNF brain derived growth factor
Bm bone marrow
BrdU bromodeoxyuridine
BSA bovine serum albumine
CAA cerebral amyloid angiopathy
CdK cyclin dependent kinase
CNS central nervous system
CNTF cilliary neurtrophic factor
CR caloric restriction
DAB 3,3’-diaminobenzidine
DCX doublecortin
DG dentate gurus
EC entorhinal cortex
EGF endothelial growth factor
ES cells embryonic stem cells
FAD familial Alzheimer’s disease
FcgR Fc gamma receptor
FGF fibroblast growth factor
GCL granular cell layer
GFAP glial fibrillary acid protein
GFP enhanced green fluorescent protein
Gp glyco protein
HPA hypothalamo-pituitary axis
IDE insulin degrading enzyme
IgG immune globuline G
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IGF insuline-like growth factor
IL inter leukine
INF interferon
LIFR leucocyte inhibitory factor receptor
LPS lipo poly saccharide
LRP lipoprotein receptor related protein
LTP long term potentiation
ML molecular layer
Nct nicastrin
NeuN neuronal nuclei
NGF nerve growth factor
NO nitric oxide
NSAID non steroidal anti inflammatory drug
OB olfactory bulb
PB phosphate buffer
PBS phosphate buffered saline
PEN-2 presenilin-enhancer
PFA paraformaldehyde
PS presenilin
PSA-NCAM polysialyated acid neural cell adhesion molecule
S subiculum
sAPP soluble amyloid precursor protein
SVZ sub ventricular zone
TBS tris buffered saline
TNF tumor necrosis factor
VEGF vascular endothelial growth factor
WT wild type
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